medRxiv preprint doi: https://doi.org/10.1101/2023.08.18.23293746; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# Emergence of neutralizing antibodies associates with clearance of SARS-CoV-2 during HIV-mediated immunosuppression

3

Farina Karim<sup>1,2</sup>, Mallory Bernstein<sup>1</sup>, Zesuliwe Jule<sup>1</sup>, Gila Lustig<sup>3</sup>, Janine-Lee Upton<sup>1</sup>, Yashica Ganga<sup>1</sup>, Khadija Khan<sup>1,2</sup>, Kajal Reedoy<sup>1</sup>, Matilda Mazibuko<sup>1</sup>, Katya Govender<sup>1</sup>, Kershnee Thambu<sup>1</sup>, Nokuthula Ngcobo<sup>1</sup>, Elizabeth Venter<sup>4,5</sup>, Zanele Makhado<sup>4,5</sup>, Willem Hanekom<sup>1,6</sup>, Anne von Gottberg<sup>4,5</sup>, Quarraisha Abdool Karim<sup>3,7</sup>, Salim S. Abdool Karim<sup>3,7</sup>, Nithendra Manickchund<sup>8</sup>, Nombulelo Magula<sup>9</sup>, Bernadett I. Gosnell<sup>8</sup>, Penny L. Moore <sup>3,4,5,10</sup>, Richard J. Lessells<sup>3,11</sup>, Tulio de Oliveira<sup>3,11,12,13</sup>, Mahomed-Yunus S. Moosa<sup>8</sup>, Alex Sigal<sup>1,2,3</sup>

10

<sup>1</sup>Africa Health Research Institute, Durban, South Africa. <sup>2</sup>School of Laboratory Medicine and Medical 11 Sciences, University of KwaZulu-Natal, Durban, South Africa. <sup>3</sup>Centre for the AIDS Programme of 12 13 Research in South Africa, Durban, South Africa. <sup>4</sup>SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 14 <sup>5</sup>National Institute for Communicable Diseases of the National Health Laboratory Service, 15 Johannesburg, South Africa. <sup>6</sup>Division of Infection and Immunity, University College London, London, 16 17 UK. <sup>7</sup>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States. <sup>8</sup>Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, 18 University of KwaZulu-Natal, Durban, South Africa. 9Department of Internal Medicine, Nelson R. 19 20 Mandela School of Medicine, University of Kwa-Zulu Natal, Durban, South Africa. <sup>10</sup>Institute of Infectious 21 Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. <sup>11</sup>KwaZulu-Natal 22 Research Innovation and Sequencing Platform, Durban, South Africa. <sup>12</sup>Centre for Epidemic Response 23 and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa. <sup>13</sup>Department of Global Health, University of Washington, Seattle, USA. 24

25

To design effective vaccines and other immune interventions against a pathogen, it is 26 necessary to know which aspect of immunity associates with protection. We 27 28 investigated whether neutralizing antibodies associate with infection clearance in longterm SARS-CoV-2 infection during HIV-mediated immunosuppression. We monitored 29 neutralizing antibody activity against SARS-CoV-2 over 1 to 2 years in five participants 30 31 with advanced HIV disease and delayed control of HIV viremia. These participants had persistent SARS-CoV-2 infection ranging from 110 to 289 days which was associated 32 with low or undetectable neutralizing antibody responses. SARS-CoV-2 clearance was 33 associated with the emergence of neutralizing antibodies and occurred in two 34 participants before suppression of HIV viremia, but after some CD4 T cell 35 reconstitution. Vaccination only further increased neutralizing antibody levels in the 36 37 advanced HIV disease participants who achieved HIV suppression pre-vaccination. 38 During the prolonged SARS-CoV-2 infection we observed widespread evolution which 39 was particularly pronounced in one Delta variant infection. This resulted in high-level escape from Delta-elicited neutralizing antibodies and a virus antigenically distinct 40 from both ancestral SARS-CoV-2 and Omicron XBB in hamster experimental infections. 41 42 The results offer new evidence that neutralizing antibodies associate with SARS-CoV-2 clearance and argue that successful management of HIV may be necessary to curtail 43 long-term infection and evolution of co-infecting pathogens. 44

<sup>45</sup> NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### Introduction 46

Neutralizing antibodies are a key correlate of protection against most viral infections<sup>1,2</sup>. During 47 48 the Covid-19 pandemic, evolution of new viral variants reduced the ability of neutralizing antibodies elicited by previous infection or vaccination to prevent new symptomatic infections, 49 50 although protection from more severe disease was generally maintained<sup>3</sup>. One possibility of how SARS-CoV-2 variants arise is evolution during long-term infection in immunosuppressed 51 individuals<sup>4-16</sup>. Such evolution in immunocompromised hosts is not unique to SARS-CoV-2 52 53 and has been observed in influenza and salmonella infections<sup>17,18</sup>.

Case studies of SARS-CoV-2 infections in immunosuppressed individuals show prolonged 54 55 infection and evolution of genomic changes in the SARS-CoV-2 spike protein associated with escape from neutralizing antibodies<sup>13</sup>. Mutations outside of spike are also common and may 56 57 confer different functions<sup>19,20</sup>. SARS-CoV-2 long-term infection and evolution happens in some 58 individuals who are immunosuppressed because of long-term uncontrolled HIV infection, 59 termed advanced HIV disease<sup>4-6,15</sup>. Here, immunosuppression occurs because HIV infection depletes CD4 T cells by a variety of mechanisms that include death of both HIV-infected<sup>21-24</sup> 60 61 and uninfected bystander or incompletely infected cells<sup>25-29</sup>. Advanced HIV disease is defined 62 as a CD4 T cell count lower than 200 cells/microliter (a normal CD4 T cell count is about 1000 cells/microliter). This level of CD4 T cell depletion is known to result in vulnerability to multiple 63 64 pathogens. One example is Mycobacterium tuberculosis, one of the cardinal infections leading 65 to the death of people living with HIV (PLWH) in the pre-antiretroviral therapy (ART) era<sup>30,31</sup>.

While there can be multiple reasons for immunosuppression<sup>7,16,32-34</sup>, the number of people 66 67 globally with immunosuppression because of advanced HIV disease may be considerable. In South Africa alone, the estimated number of PLWH is about 8 million<sup>35</sup>. About 1 in 10 are 68 thought to meet the criteria for advanced HIV disease<sup>36,37</sup> - an estimated 800,000 people. 69 70 Vaccination could potentially be a strategy to elicit a better immune response in people with advanced HIV disease. However, for SARS-CoV-2, vaccines were reported to be less effective 71 at eliciting a neutralizing antibody response in PLWH with CD4 counts lower than 200 72 cells/microliter<sup>38-40</sup>. 73

74 We have previously reported one case where advanced HIV disease interferes with SARS-CoV-2 clearance and leads to SARS-CoV-2 evolution (participant 27 in this study)<sup>4,5</sup>. The virus 75 76 which evolved in this participant over 6 months gained immune escape from neutralizing antibodies elicited by SARS-CoV-2 infection and Pfizer BNT162b2 mRNA vaccination. Here 77 78 we tracked SARS-CoV-2 infection in five participants with advanced HIV disease and failure 79 to adhere to ART, who eventually suppressed HIV viremia. All had prolonged SARS-CoV-2 80 infection. Clearance was associated with emergence of neutralizing antibodies. Among the viruses we isolated from these participants, SARS-CoV-2 originating in a Delta variant 81 82 infection evolved the most antibody escape mutations and had high-level escape from Deltaelicited neutralizing antibodies. However, it did not escape the current population neutralizing 83 antibody immunity to SARS-CoV-2. 84

85

### Results 86

### Advanced HIV disease leads to long-term SARS-CoV-2 infection and evolution 87

Five participants with advanced HIV disease and HIV viremia are described in this study. They 88 are part of an observational longitudinal cohort of SARS-CoV-2 infection in South Africa 89 numbering 994 participants, including 113 PLWH with a CD4 T cell count lower than 200 90 cells/microliter at enrollment (Table S1). Participant information was de-identified and 91 92 participants assigned numbers. The linkage between number and identifying information is only known to the clinical team of the study. The five participants, whose de-identified numbers 93 were 27, 96, 127, 255, and 209, were between 20 and 50 years old and had a Covid-19 94 95 diagnosis date ranging from September 2020 to December 2021 (Table S2). All participants were living with HIV before SARS-CoV-2 infection and participant 255 was HIV-infected by 96 97 mother-to-child transmission. Participants were outpatients for 82% of study visits. During 98 each study visit, a combined nasopharyngeal and oropharyngeal swab was taken to detect 99 SARS-CoV-2 by qPCR cycle threshold (Ct, Figure 1A) which is inversely proportional to SARS-CoV-2 titer. The virus was isolated from the swab by outgrowth and/or sequenced when 100 101 viral titers were sufficient (Ct<30 for sequencing and Ct<25 for isolation). The timepoints and 102 titers of successfully sequenced samples are shown in Figure 1A as red circles. The duration of SARS-CoV-2 infection, calculated as time from first diagnostic to last qPCR positive SARS-103 104 CoV-2 test was a median of 207 days, and ranged from 110 to 289 days (Table S2). Four of 105 the participants were enrolled soon after diagnosis. One participant (255) was enrolled in the study in December 2021 during the Omicron infection wave. However, a record of a positive 106 107 qPCR result for SARS-CoV-2 was present from September 2021, corresponding the Delta variant infection wave (Figure 1A). 108

109 Participants were initiated on ART in line with current national guidelines and received 110 adherence counselling from the clinical team. The ART regimen used was the integrase inhibitor dolutegravir (DTG), combined with the nucleotide/nucleoside reverse transcriptase 111 inhibitors tenofovir (TFV) and lamivudine (3TC). The five participants described here had 112 delayed control of HIV viremia (Figure 1B). Retrospective detection of ART levels in this group 113 114 by liquid chromatography coupled with tandem mass spectrometry showed non-adherence to the DTG based regimen. Green bars in Figure 1B show the time when DTG started to be 115 116 consistently detected and Figure S1 shows study visits where DTG, TFV, and 3TC were detected. Surprisingly, other antiretroviral drugs were also detected, possibly previously 117 initiated regimens (Figure S1, blue rectangles). The participants eventually adhered to DTG 118 based ART (Figure S1, green rectangles), leading to HIV suppression observed as a decline 119 in HIV viremia to below the threshold of assay detection (40 HIV RNA copies/mL) during the 120 121 study (Figure 1B).

122 Four of the participants were vaccinated with two doses of the Pfizer BNT162b2 mRNA vaccine and vaccination times are shown as vertical dashed lines in Figure 1A-B. The fifth 123 (127) was vaccinated with only one dose because the participant developed synovial 124 inflammation in the wrists and hands 6 days post-first vaccine dose, a rare adverse event 125 associated with Covid-19 mRNA vaccines<sup>41,42</sup>. The interval between doses approximately 126 followed the South African guidelines at the time of vaccination, which was 6 weeks, although 127 some variation occurred. 128

We next determined the infecting variant by sequencing. Alignment of sequenced SARS-CoV-129 2 showed that, consistent with the infection date (Figure 1A), the participant designated 27 130 was infected with ancestral SARS-CoV-2 (Figure 1C, grey circles) and the participant 131

132 designated 96 was infected with the Beta variant (Figure 1C, purple circles). Participant 127 was initially infected with a Beta variant (Figure 1C, purple triangles) but the last sequence 133 was a Delta variant (Figure 1C, highlighted in red), likely a re-infection which occurred during 134 the Delta infection wave in South Africa. Participant 255 was infected with the Delta variant 135 (Figure 1C, blue circles), consistent with a continuous infection from the first positive 136 diagnostic test in September 2021. Participant 209 was infected with the Omicron BA.1 137 subvariant (Figure 1C, green circles), but the sequence from the last timepoint was an 138 139 Omicron BA.5 subvariant (Figure 1C, highlighted in red), likely a re-infection.

We next analyzed non-synonymous changes across the SARS-CoV-2 genome from each 140 141 sequenced timepoint per participant using the Stanford Coronavirus Antiviral and Resistance Database (https://covdb.stanford.edu/sierra/sars2/by-sequences/). Three of the participants, 142 143 27, 96 and 255, had extensive non-synonymous changes in the circulating virus, while two, 144 127 and 209, had few changes but showed an abrupt shift in sequence consistent with reinfection with a different variant or sub-variant (Figure S2). Both 27 and 255 had multiple 145 146 substitutions in the receptor binding domain (RBD) of the spike gene predicted to lead to escape from neutralizing antibodies. These included E484K, K417T and F490S<sup>43-47</sup> in the virus 147 from participant 27 and K417T, L452Q, A475V, and E484A<sup>46-50</sup> in the virus from participant 148 149 255.

### 150 Long-term SARS-CoV-2 infection clearance associates with emergence of neutralizing antibodies 151

To investigate the relationship between the neutralizing antibody response and SARS-CoV-2 152 153 clearance, we isolated and expanded at least one SARS-CoV-2 virus from each participant 154 and tested the neutralizing capacity of the participant's plasma against the autologous outgrown viruses at the different timepoints post-diagnosis. Figure 2A shows SARS-CoV-2 155 156 viral titers through time for each participant up to and including the virus clearance timepoint, where clearance was defined as two or more consecutive timepoints where SARS-CoV-2 is 157 158 undetectable (see Figure 1A).

The neutralization capacity of participant plasma was determined throughout this work by a 159 focus forming assay with the live virus isolates (Figure S3). To quantify the result, we present 160 the focus reduction neutralization test 50 value (FRNT<sub>50</sub>), the inverse of the plasma dilution 161 required for 50% neutralization. Ongoing SARS-CoV-2 infection was correlated with low 162 FRNT<sub>50</sub> values at or below the level of detection (Figure 2B). Strikingly, in all cases, there was 163 a strong increase in neutralization capacity against the autologous viruses at SARS-CoV-2 164 165 clearance (Figure 2B, last timepoint in each graph). The absolute FRNT<sub>50</sub> value which was associated with viral clearance varied between participants. In participant 96 it also varied 166 between virus isolates. In participant 255, who had undetectable neutralizing antibody levels 167 before SARS-CoV-2 clearance, the FRNT<sub>50</sub> value became detectable but remained relatively 168 low. 169

We examined the HIV viral load (Figure 2C) and CD4 T cell counts (Figure 2D) at each 170 171 timepoint per participant. While participants 27, 96, and 127 showed HIV suppression at SARS-CoV-2 clearance, participant 209 did not have full suppression (Figure 2C, rightmost 172 panel) and participant 255 was unsuppressed, with an HIV viral load of about 10<sup>4</sup> RNA 173 174 copies/mL (Figure 2C, panel second from right). Immune reconstitution measured in terms of an increase in CD4 T cell counts occurred in every participant (Figure 2D), although CD4 175 counts remained at 100 cells/microliter or below for 4 out of 5 participants. Participants had a 176 177 gradual increase in CD4 count to the time of SARS-CoV-2 clearance. However, participant

255, who did not have a suppressed HIV viral load at clearance, showed CD4 T cell 178 reconstitution which plateaued at a timepoint where SARS-CoV-2 was not yet cleared (Figure 179 180 2D, second from right).

### Poor vaccine neutralizing antibody response in advanced HIV disease participants with 181 182 HIV viremia

We investigated the neutralizing antibody response elicited by vaccination in the advanced 183 184 HIV disease participants and compared the response to participants, either PLWH or HIV negative, who did not have immunosuppression (Tables S3-S4). All participants received the 185 Pfizer BNT162b2 mRNA vaccine. 186

We tested for neutralizing antibodies against ancestral virus, the Beta, Delta and Omicron 187 BA.1 variants, as well as anti-spike antibody levels, at baseline and after each vaccine dose 188 (Figure 3A). In the three participants with suppressed HIV at vaccination (27, 96, and 127), 189 there was an increase in neutralization capacity for all strains/variants tested after the first, 190 191 and if administered, second dose of the vaccine, and a similar increase in overall anti-spike 192 antibodies. In participant 127, who received only one vaccine dose, vaccine elicited neutralization waned quickly, with neutralization capacity dropping approximately 10-fold in 193 about 4 months against all viruses tested. In participant 27, neutralizing antibodies to Omicron 194 195 BA.1 showed rapid waning (Figure 3A).

In participants 255 and 209, HIV viremia was present at vaccination (Figure 1B). Participant 196 255 cleared SARS-CoV-2 at the vaccine baseline visit, before vaccination was administered. 197 Participant 255 still had SARS-CoV-2 infection at vaccination (Figure 1A). Both 255 and 209 198 199 showed a poor initial response to the vaccine (Figure 3A). For 255, neutralization capacity 200 decreased to below limit of quantification after the first dose and remained at that level after 201 the second dose. For 209, neutralization capacity increased with time, but not at two weeks post-vaccination, the first post-vaccination timepoint tested and expected peak of the 202 203 neutralization response to the vaccine (Figure 3A, right panel).

To compare our results to participants without advanced HIV disease who were also 204 previously SARS-CoV-2 infected, we tested the antibody neutralization response after each 205 206 vaccine dose in five participants with either suppressed HIV or who were HIV negative (see Table S3 for participant details). These participants showed a relatively homogenous 207 208 response, with a large fold-increase post-first dose, usually followed by limited waning, then a 209 smaller fold-increase in neutralizing capacity post-second dose (Figure 3B).

Interestingly, we observed that anti-spike binding antibody levels mirrored well the neutralizing 210 antibody response to the different viral isolates. The exceptions were the two advanced HIV 211 disease participants with HIV viremia at vaccination. For participant 255, the first timepoint 212 post-vaccination showed a strong increase in anti-spike antibodies but not neutralization 213 capacity, and this was also observed for participant 209 (who also had uncleared SARS-CoV-214 215 2) at the baseline visit before administration of the first antibody dose.

216 We quantified the response post-second dose in a larger group of previously infected participants with no advanced HIV disease (Table S4), who were PLWH (n=10) or HIV 217 218 negative (n=16). This group included the control group of five participants with detailed longitudinal samples described above. In all participants, we tested for neutralizing antibodies 219 against ancestral virus, the Beta, Delta and Omicron BA.1 variants (Figure 3C). The three 220 221 advanced HIV disease participants with ART suppressed HIV at the time of vaccination showed a vaccine mediated increase in neutralization of all four viruses (Figure 3C, green 222

223 lines). In contrast, neutralizing antibody remained low against the four viruses in the two advanced HIV disease participants with unsuppressed HIV (Figure 3C, red lines). Unlike the 224 responses of the advanced HIV disease participants with suppressed HIV, these responses 225 226 were distinct from the neutralizing antibody vaccine responses of the participants with no 227 advanced HIV disease.

### Low XBB.1.5-infection elicited cross-neutralization of ancestral and Delta-evolved 228 229 viruses in hamster infections

230 The degree to which neutralizing antibody immunity elicited by infection with one virus strain can cross-neutralize a second strain is a measure of the antigenic distance between them. 231 232 However, given that SARS-CoV-2 seroprevalence in South Africa was approximately 70% pre-Omicron<sup>51</sup>, we could not use human sera to measure antigenic distance between recent 233 Omicron subvariants such as XBB and other strains as we would be unlikely to find XBB 234 235 infected individuals who were uninfected with earlier variants. We have therefore investigated 236 cross-neutralization of ancestral SARS-CoV-2, the Omicron XBB.1.5 subvariant, and two of 237 the evolved SARS-CoV-2 strains with the most antibody escape mutations (Figure 4A) in the 238 Syrian golden hamster experimental infection model. The two evolved viruses were the virus 239 evolved from ancestral SARS-CoV-2 in participant 27 after a 190-day infection (27-D190), and the virus evolved from the Delta variant in participant 255 after a 237-day infection (255-D237). 240 241 Sixteen days post-infection, plasma samples from uninfected and infected animals were tested against the autologous (infecting) virus as well as the three other viruses to determine 242 243 cross-neutralization (Figure 4B).

244 Plasma from uninfected animals did not neutralize any of the viruses (Figure 4C). Plasma from infected animals most potently neutralized the autologous virus and cross-neutralized the 245 other viruses less well (Figure 4D-G). The animals not infected with Omicron XBB.1.5 did not 246 247 have a substantial cross-neutralization of XBB.1.5 (Figure 4D-F), and animals infected with XBB.1.5 failed to develop a cross-neutralizing response to the other viruses tested (Figure 248 249 4G).

To better visualize the antigenic distances between the viruses, we used antigenic cartography 250 (Figure 4H) which maps the distances between multiple viruses and the sera elicited by their 251 infections<sup>52-54</sup>. Here, each square of distance corresponds to a 2-fold drop in neutralizing 252 capacity. Using this visualization, we observed that 27-D190 was antigenically close to 253 254 ancestral virus from which it evolved. In contrast, XBB.1.5 was antigenically far from all the 255 other viruses tested. The Delta evolved 255-D237 was antigenically distinct from both 256 ancestral SARS-CoV-2 and Omicron XBB.1.5.

### Evolved Delta variant escapes Delta but not Omicron XBB-elicited neutralizing 257 258 antibodies

People were likely infected through the course of the pandemic with multiple SARS-CoV-2 259 260 strains/variants, and therefore their neutralizing antibody responses may have a different pattern than those we observed in the singly infected hamsters. As we have previously 261 characterized the 27-D190 evolved virus<sup>4,20</sup>, here we tested the Delta variant evolved 255-262 D237 virus which had mutations predicted to result in immune escape from neutralizing 263 antibodies (Figure 4A). We tested this virus against plasma panels from participants infected 264 in the Delta, Omicron subvariant BA.1, and Omicron subvariant XBB infection periods in South 265 Africa (see Table S5 for participant details). 266

267 We first tested 255-D237 against plasma from participants infected with the Delta variant. We observed that, relative to the Delta variant virus, the 255-D237 had over 18-fold lower FRNT<sub>50</sub> 268 (Figure 5A), escape similar to Omicron BA.1 relative ancestral virus in participants vaccinated 269 with ancestral virus based vaccines<sup>55</sup>. We then tested this virus against plasma from Omicron 270 271 BA.1 infected participants. As we reported previously, we found Omicron BA.1 elicited 272 neutralizing immunity to be relatively low<sup>56</sup>. The 255-D237 evolved virus had a 6.5-fold escape of neutralization relative to the Omicron BA.1 virus in this group, with some of the neutralization 273 274 values for 255-D237 falling below the threshold of quantification (Figure 5B).

We then proceeded to test 255-D237 against plasma from vaccinated participants with 275 breakthrough Omicron BA.1 infection. As we previously reported<sup>56</sup>, the vaccinated/BA.1 276 infected group had stronger Omicron BA.1 virus neutralization as well as better cross-277 278 neutralization of other variants compared to the unvaccinated group. We observed that 279 neutralizing antibody immunity in this group neutralized the 255-D237 virus to a similar extent as the BA.1 virus (Figure 5C). Lastly, we tested against plasma from individuals infected during 280 281 the period when Omicron XBB subvariants were dominant in South Africa (from November-282 December 2022, https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sarscov-2-genomic-surveillance-update/ accessed August 8, 2023). These participants are also 283 expected to have immunity from previous infections, including pre-Omicron variants. In this 284 group there was no escape of the 255-D237 virus relative to the XBB.1.5 subvariant (Figure 285 5D). 286

### 287 Discussion

288 Here we characterized five long-term SARS-CoV-2 infections in individuals with advanced HIV disease who had HIV viremia upon study enrollment. We found that SARS-CoV-2 clearance 289 was associated with the emergence of a neutralizing antibody response in every case. Based 290 291 on vaccine trials, neutralizing antibodies are a known correlate of protection against symptomatic SARS-CoV-2 infection<sup>2</sup>. However, this study is, to our knowledge, the first to 292 293 demonstrate an association between the emergence of an antibody response and SARS-CoV-294 2 clearance in long-term infection in a group of participants. The study has the limitation that, 295 despite the large number of participants followed in our cohort, the number of participants with advanced HIV disease and persistent HIV viremia was small. The potentially key role of the 296 297 neutralizing antibody response in clearing SARS-CoV-2 which we found in this study is 298 consistent with observations that B cell depletion with rituximab leads to persistent SARS-CoV-2 infection<sup>57-60</sup>. 299

300 We observed that the neutralizing antibody response did not need to be very strong to associate with SARS-CoV-2 clearance, as demonstrated for participant 255. A related 301 302 observation was that SARS-CoV-2 was cleared despite HIV viremia being present. Incomplete HIV suppression at SARS-CoV-2 clearance was also observed in participant 209. Some 303 reconstitution of CD4 T cell numbers occurred in all participants, including the HIV viremic 304 participants, prior to SARS-CoV-2 clearance. CD4 T cell reconstitution likely occurred because 305 306 of ART initiation, even if initiation was partial. Since T cell help is essential to generate an effective antibody response<sup>61</sup>, this reconstitution may have led to the production of neutralizing 307 antibodies to SARS-CoV-2. 308

309 We found that the Pfizer BNT162b2 mRNA vaccine was effective in increasing binding and 310 neutralizing antibodies against SARS-CoV-2 variants in participants with advanced HIV disease who had ART suppressed HIV viremia. It was not effective in the two participants in 311 312 whom HIV viremia was still present. This agrees with previous studies showing a less effective

neutralizing antibody responses to vaccines in individuals with low CD4 T cell counts<sup>38-40</sup>. 313

- Therefore, vaccination in the absence of HIV suppression may not be an effective strategy to 314
- increase immunity in people with advanced HIV disease. 315

Interestingly, while binding antibody levels tracked closely with neutralization capacity, the two 316 viremic advanced HIV disease participants showed instances where binding antibodies were 317 elevated without a rise in neutralizing antibody activity, perhaps because of a lack of 318 319 neutralization potency, which can be associated with poor B cell affinity maturation<sup>62,63</sup>.

320 All advanced HIV disease participants evolved SARS-CoV-2 mutations in their circulating viruses in long-term infection. Two of the participants, infected with ancestral and Delta variant 321 322 viruses respectively, had evolved multiple known antibody escape mutations including E484K, E484A, K417T, F490S, L452Q, and A475V<sup>43-50</sup>. Examining the consequences of these 323 mutations in the hamster infection model showed that the virus evolved from the Delta variant 324 had considerable antigenic distance from both ancestral SARS-CoV-2 and the Omicron 325 326 XBB.1.5 subvariant. Interestingly, hamster infection with XBB.1.5 failed to elicit neutralizing immunity not only to the Delta variant evolved virus but also to ancestral SARS-CoV-2, in 327 328 agreement with recent results<sup>64</sup>. The Delta variant evolved virus also showed extensive 329 escape from immunity elicited by Delta variant infections in people. However, it did not escape more recent neutralizing immunity from vaccinated individuals with Omicron BA.1 330 331 breakthrough infection, nor from neutralizing immunity elicited by Omicron XBB subvariants. It is likely that most of the BA.1 and XBB infected group have immunity from pre-Omicron 332 infections<sup>51,65</sup>, and in the case of the XBB group, other Omicron subvariant infections<sup>66</sup>. 333 Therefore, in contrast to the hamster experimental infections which used one virus, individuals 334 enrolled during the XBB period likely had hybrid immunity from multiple exposures, leading to 335 wider neutralization breadth<sup>56</sup> and accounting for the difference in the results. 336

337 In conclusion, we have found new evidence that neutralizing antibodies associate with SARS-CoV-2 clearance and are likely required for such clearance to happen. However, the levels 338 need not be high. Furthermore, we have found that, while SARS-CoV-2 can evolve extensively 339 340 in long-term infection in advanced HIV disease, neutralizing antibody immunity from recent 341 infections, most likely combined with that acquired in past infections, may neutralize some of the viruses evolved in this way. It is likely that such evolution during long-term infection in 342 343 immunosuppressed individuals occurs in other pathogens in HIV co-infections. Therefore, investment in an effective global HIV treatment strategy may be necessary to reduce the 344 345 chances that this type of evolutionary process results in a pathogen with pandemic potential.

346

### Methods 347

### 348 Informed consent and ethical statement

All blood samples used for neutralization studies, nasopharyngeal swabs from the advanced 349 350 HIV disease participants for outgrowth and sequencing, as well as nasopharyngeal swabs for 351 isolation of the ancestral/D614G, Beta, and Delta virus were obtained after written informed consent from adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective 352 cohort of SARS-CoV-2 infected individuals at the Africa Health Research Institute approved 353 by the Biomedical Research Ethics Committee at the University of KwaZulu–Natal (reference 354 BREC/00001275/2020). The Omicron/BA.1 virus was isolated from residual swab used for 355 diagnostic testing (Witwatersrand Human Research Ethics Committee reference M210752). 356 357 The nasopharyngeal swab for isolation of the Omicron XBB.1.5 subvariant was collected after written informed consent as part of the COVID-19 transmission and natural history in KwaZulu-358

Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care in the 359 Centre for the AIDS Programme of Research in South Africa (CAPRISA) study and approved 360 by the Biomedical Research Ethics Committee at the University of KwaZulu–Natal (reference 361 BREC/00001195/2020, BREC/00003106/2021). 362

### Reagent availability statement 363

Viral isolates are available upon reasonable request. Sequences of isolated SARS-CoV-2 364 365 used in this study have been deposited in GISAID with accession numbers as follows:

Virus	GISAID	Virus	GISAID
D614G	EPI_ISL_602626.1	0127-D10	EPI_ISL_16508746
Beta	EPI_ISL_678615	0127-D24	EPI_ISL_16508747
Delta	EPI_ISL_3118687	0127-D31	EPI_ISL_16508748
BA.1	EPI_ISL_7886688	0127-D38	EPI_ISL_16508749
0027-D6	EPI_ISL_15541746	0127-D54	EPI_ISL_18030392
0027-D20	EPI_ISL_15541747	0127-D68	EPI_ISL_16508751
0027-D34	EPI_ISL_15541748	0127-D192	EPI_ISL_14666773
0027-D71	EPI_ISL_15541749	0255-D209	EPI_ISL_14599778
0027-D106	EPI_ISL_15541750	0255-D211	EPI_ISL_14599779
0027-D190	EPI_ISL_2397313	0255-D219	EPI_ISL_14599780
0096-D1	EPI_ISL_14666761	0255-D237	EPI_ISL_13986497
0096-D15	EPI_ISL_14666763	0209-D5	EPI_ISL_18030393
0096-D32	EPI_ISL_13986492	0209-D26	EPI_ISL_18030394
0096-D68	EPI_ISL_18030390	0209-D144	EPI_ISL_12970433
0096-D77	EPI_ISL_18030391	0209-D159	EPI_ISL_14666777
0096-D110	EPI_ISL_14666766		

366

### 367 **Clinical laboratory testing**

SARS-CoV-2 Ct and HIV viral load quantification was performed from a nasopharyngeal swab 368 universal transport medium aliquot and 4 ml EDTA tube of blood respectively at an accredited 369 diagnostic laboratory (Molecular Diagnostic Services, Durban, South Africa). The CD4 count 370

was performed by an accredited diagnostic laboratory (Ampath, Durban, South Africa). 371

372 Detection of ART concentrations in plasma by LC-MS/MS

Sample analysis was performed using an Agilent High Pressure Liquid Chromatography 373 (HPLC) system coupled to the AB Sciex 5500, triple quadrupole mass spectrometer equipped 374 with an electrospray ionization (ESI) TurbolonSpray source. The LC-MS/MS method was 375 developed and optimized for the quantitation of tenofovir, lamivudine and dolutegravir in the 376 377 same sample. A protein precipitation extraction method using acetonitrile was used to process 378 50 µL plasma samples. 50 µL of water and 50 µL of ISTD solution was added and the sample was briefly mixed. 150 µL of acetonitrile was subsequently added to facilitate protein 379 380 precipitation, vortex mixed and centrifuged at 16000 g for 10 min at 4°C. 170 µL of the clear supernatant was then transferred to a clean micro-centrifuge tube and dried down using a 381 SpeedVac dryer set at 40°C. The dried samples were then reconstituted in 100 µL of 0.02% 382 sodium deoxycholate (Sigma) in Millipore filtered water, vortex mixed, briefly centrifuged, 383 placed in a small insert vial, capped, placed in the auto sampler compartment (maintained at 384 385 4°C) and analyzed using LC-MS/MS. The analytes were separated on an Agilent Zorbax Eclipse Plus C18 HPLC column using gradient elution. The column oven was set at 40°C, a 386 sample volume of 2 µL was injected and the flow rate was set to 0.2 mL/min. Mobile phase A 387

medRxiv preprint doi: https://doi.org/10.1101/2023.08.18.23293746; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

consisted of water with 0.1% formic acid and B consisted of acetonitrile with 0.1% formic acid.
The drug analytes were monitored using multiple-reaction monitoring mode for positive ions
except for efavirenz which was monitored in the negative ion scan mode. Analyst software,
version 1.6.2 was used for quantitative data analysis. Blanked values for EFV, FTC and TFV
were in the range of 3 ng/mL and this was set as the detection limit.

### 393 Whole-genome sequencing

394 RNA was extracted on an automated Chemagic 360 instrument, using the CMG-1049 kit (Perkin Elmer, Hamburg, Germany). The RNA was stored at -80°C prior to use. Libraries for 395 whole genome sequencing were prepared using either the Oxford Nanopore Midnight protocol 396 with Rapid Barcoding or the Illumina COVIDseq Assay. For the Illumina COVIDseq assay, the 397 398 libraries were prepared according to the manufacturer's protocol. Briefly, amplicons were 399 tagmented, followed by indexing using the Nextera UD Indexes Set A. Sequencing libraries 400 were pooled, normalized to 4 nM and denatured with 0.2 N sodium acetate. An 8 pM sample library was spiked with 1% PhiX (PhiX Control v3 adaptor-ligated library used as a control). 401 402 We sequenced libraries on a 500-cycle v2 MiSeg Reagent Kit on the Illumina MiSeg instrument (Illumina). On the Illumina NextSeg 550 instrument, sequencing was performed 403 using the Illumina COVIDSeq protocol (Illumina Inc, USA), an amplicon-based next-generation 404 405 sequencing approach. The first strand synthesis was carried using random hexamers primers from Illumina and the synthesized cDNA underwent two separate multiplex PCR reactions. 406 407 The pooled PCR amplified products were processed for tagmentation and adapter ligation 408 using IDT for Illumina Nextera UD Indexes. Further enrichment and cleanup was performed as per protocols provided by the manufacturer (Illumina Inc). Pooled samples were quantified 409 using Qubit 3.0 or 4.0 fluorometer (Invitrogen Inc.) using the Qubit dsDNA High Sensitivity 410 assay according to manufacturer's instructions. The fragment sizes were analyzed using 411 TapeStation 4200 (Invitrogen). The pooled libraries were further normalized to 4nM 412 concentration and 25 µL of each normalized pool containing unique index adapter sets were 413 414 combined in a new tube. The final library pool was denatured and neutralized with 0.2N sodium 415 hydroxide and 200 mM Tris-HCL (pH7), respectively. 1.5 pM sample library was spiked with 416 2% PhiX. Libraries were loaded onto a 300-cycle NextSeg 500/550 HighOutput Kit v2 and run 417 on the Illumina NextSeg 550 instrument (Illumina, San Diego, CA, USA). For Oxford Nanopore 418 sequencing, the Midnight primer kit was used as described by Freed and Silander55. cDNA synthesis was performed on the extracted RNA using LunaScript RT mastermix (New England 419 420 BioLabs) followed by gene-specific multiplex PCR using the Midnight Primer pools which produce 1200bp amplicons which overlap to cover the 30-kb SARS-CoV-2 genome. 421 422 Amplicons from each pool were pooled and used neat for barcoding with the Oxford Nanopore Rapid Barcoding kit as per the manufacturer's protocol. Barcoded samples were pooled and 423 bead-purified. After the bead clean-up, the library was loaded on a prepared R9.4.1 flow-cell. 424 A GridION X5 or MinION sequencing run was initiated using MinKNOW software with the 425 base-call setting switched off. We assembled paired-end and nanopore.fastq reads using 426 427 Genome Detective 1.132 (https://www.genomedetective.com) which was updated for the 428 accurate assembly and variant calling of tiled primer amplicon Illumina or Oxford Nanopore reads, and the Coronavirus Typing Tool. For Illumina assembly, GATK HaploTypeCaller --429 430 min-pruning 0 argument was added to increase mutation calling sensitivity near sequencing gaps. For Nanopore, low coverage regions with poor alignment quality (<85% variant 431 homogeneity) near sequencing/amplicon ends were masked to be robust against primer drop-432 433 out experienced in the Spike gene, and the sensitivity for detecting short inserts using a regionlocal global alignment of reads, was increased. In addition, we also used the wf artic (ARTIC 434 435 SARS-CoV-2) pipeline as built using the nextflow workflow framework. In some instances, mutations were confirmed visually with .bam files using Geneious software V2020.1.2 436

medRxiv preprint doi: https://doi.org/10.1101/2023.08.18.23293746; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

437 (Biomatters). The reference genome used throughout the assembly process was NC 045512.2 (numbering equivalent to MN908947.3). To determine which SARS-CoV-2 438 proteins were mutated, sequence was input into the sequence analysis application in the 439 440 Stanford Coronavirus Antiviral and Resistance Database (https://covdb.stanford.edu/sierra/sars2/by-sequences/) with HTML as output. Mutations were 441 442 then visualized in Excel relative to the infecting variant.

### 443 Phylogenetic analysis

Sequences were aligned by Nextclade version 2.9.1 (https://clades.nextstrain.org/). The json 444 file output from the Nextclade analysis was loaded into Auspice (https://auspice.us/). 445 Visualization was filtered to include reference sequences from clades 20A, 20B, 20H (Beta), 446 21J (Delta), 21M, 21K, 21L and 22B (Omicron), and the input sequences (new nodes), for a 447 448 combined 1408 genomes. The tree was then filtered to show new nodes only. Tip labels were removed and SVG downloaded for final processing using Microsoft Powerpoint software. 449

### 450 Cells

The H1299-E3 (H1299-ACE2, clone E3) cell line used in the live virus infections was derived 451 from H1299 (CRL-5803) as described in previous work<sup>55,67</sup> and propagated in growth medium 452 consisting of complete Roswell Park Memorial Institute (RPMI) 1640 with 10% fetal bovine 453 serum containing 10mM of HEPES, 1mM sodium pyruvate, 2mM L-glutamine and 0.1mM 454 455 nonessential amino acids.

### Live virus neutralization assay 456

H1299-E3 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day pre-457 infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf 458 459 for 10 min and stored at -80 °C. Aliguots of plasma samples were heat-inactivated at 56 °C for 30 min and clarified by centrifugation at 10,000 rcf for 5 min. Virus stocks were used at 460 approximately 50-100 focus-forming units per microwell and added to diluted plasma. 461 Antibody-virus mixtures were incubated for 1 h at 37 °C, 5% CO<sub>2</sub>. Cells were infected with 462 463 100  $\mu$ L of the virus–antibody mixtures for 1 h, then 100  $\mu$ L of a 1X RPMI 1640 (Sigma-Aldrich, R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888) overlay was added without 464 removing the inoculum. Cells were fixed 18 h post-infection using 4% PFA (Sigma-Aldrich) for 465 20 min. Foci were stained with a rabbit anti-spike monoclonal antibody (BS-R2B12, GenScript 466 467 A02058) at 0.5  $\mu$ g/mL in a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) in PBS. Plates were 468 incubated with primary antibody overnight at 4 °C, then washed with wash buffer containing 469 470 0.05% Tween-20 in PBS. Secondary goat anti-rabbit HRP conjugated antibody (Abcam 471 ab205718) was added at 1 µg/mL and incubated for 2 h at room temperature with shaking. TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50 µL per well and 472 473 incubated for 20 min at room temperature. Plates were imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot Professional built-in image analysis 474 475 (C.T.L).

- Statistics and fitting 476
- 477 All statistics and fitting were performed using custom code in MATLAB v.2019b. Neutralization data were fit to: 478
- (1)  $Tx=1/1+(D/ID_{50}).$ 479

480 Here Tx is the number of foci at plasma dilution D normalized to the number of foci in the absence of plasma on the same plate.  $ID_{50}$  is the plasma dilution giving 50% neutralization. 481

- $FRNT_{50} = 1/ID_{50}$ . Values of  $FRNT_{50} < 1$  are set to 1 (undiluted), the lowest measurable value. We note that the most concentrated plasma dilution was 1:25 and therefore  $FRNT_{50} < 25$  were extrapolated.

medRxiv preprint doi: https://doi.org/10.1101/2023.08.18.23293746; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

# perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### SARS-CoV-2 spike enzyme-linked immunosorbent assay (ELISA) 486

Two µg/mL of spike protein was used to coat 96-well, high-binding plates and incubated 487 overnight at 4°C. The plates were incubated in a blocking buffer consisting of 5% skimmed 488 milk powder, 0.05% Tween 20, 1x PBS. Plasma samples were diluted to 1:100 starting dilution 489 in a blocking buffer and added to the plates. Secondary antibody was diluted to 1:3000 or 490 1:1000 respectively in blocking buffer and added to the plates followed by TMB substrate 491 492 (Thermofisher Scientific). Upon stopping the reaction with 1 M  $H_2SO_4$ , absorbance was 493 measured at a 450nm wavelength. MAbs CR3022 and BD23 were used as positive controls 494 and Palivizumab was used as a negative control.

### 495 SARS-CoV-2 hamster infections

Golden Syrian hamsters (4-5 weeks old) were purchased from Charles River Laboratories, 496 497 USA. Experimental work was approved by the Animal Ethics Committee at the University of KwaZulu Natal (reference: REC/00004197/2022). For SARS-CoV-2 infection, hamsters were 498 499 lightly sedated with 3% isoflurane (Piramal Healthcare, Mumbai, India) and infected with virus by intranasal inoculation of 50 µL per nostril of virus solution. Plasma of infected animals and 500 uninfected controls was collected at 16 days post infection using cardiac puncture under 501 anaesthesia with 5% isoflurane. Hamsters were immediately euthanized post-puncture with 1 502 mL of 200 mg/mL sodium pentobarbitone solution (Bayer AG, Leverkusen, Germany). Plasma 503 was separated by centrifugation at 1000 x g for 10 min. Aliquots of plasma samples were heat-504 inactivated at 56 °C for 30 min and clarified by centrifugation at 10,000 rcf for 5 min. 505

### Acknowledgements 506

This study was supported by the Bill and Melinda Gates award INV-018944 (AS), Wellcome 507 Trust Award 226137/Z/22/Z (AS and PLM) and the South African Medical Research Council 508 (AS and PLM). PLM is supported by the South African Research Chairs Initiative of the 509 Department of Science and Innovation and National Research Foundation of South Africa. 510 511 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. AS wishes to thank Ron Milo, Karen Makar, and Thandi Onami 512 513 for discussion and suggestions on analysis and presentation of results.

- 514 Competing interest statement
- The authors declare no competing interests. 515

### Author contributions 516

AS and FK conceived the study and designed the study and experiments. FK, KK, MB, JU, 517 518 GL, QAK, SSAK, and AvG identified and provided virus samples. M-YSM, FK, BIG, MB, KK, NM, NMa, MM, and NN set up and managed the cohort and cohort data. KK, ZJ, KR, YG, EV, 519 520 ZM, and KG performed experiments and sequence analysis with input from AS, TdO, RJL. 521 AS, FK, MB, JU, RJL, and GL interpreted data with input from M-YSM, SSAK, WH, and TdO. 522 AS, FK, and GL prepared the manuscript with input from all authors.

- 523
- 524
- 525

#### 526 References

527 528	1	Plotkin, S. A. Correlates of Protection Induced by Vaccination. <i>Clinical and Vaccine Immunology</i> <b>17</b> , 1055-1065 (2010). doi:10.1128/CVI.00131-10
529 530 531 532 533 534 535	2 3	Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A. & Davenport, M. P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature medicine</i> , 1-7 (2021). Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S. & Davenport, M. P. Neutralising antibodies predict protection from severe COVID-19. <i>medRxiv</i> , 2022.2006.2009.22275942 (2022). 10.1101/2022.06.09.22275942
536 537 538 539 540 541 542	4	Cele, S., Karim, F., Lustig, G., San, J. E., Hermanus, T., Tegally, H., Snyman, J., Moyo-Gwete, T., Wilkinson, E., Bernstein, M., Khan, K., Hwa, SH., Tilles, S. W., Singh, L., Giandhari, J., Mthabela, N., Mazibuko, M., Ganga, Y., Gosnell, B. I., Abdool Karim, S. S., Hanekom, W., Van Voorhis, W. C., Ndung'u, T., Lessells, R. J., Moore, P. L., Moosa, MY. S., de Oliveira, T. & Sigal, A. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host &amp; Microbe</i> (2022). 10.1016/j.chom.2022.01.005
543 544 545 546 547 548	5	Karim, F., Moosa, M. Y., Gosnell, B., Sandile, C., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E., San, E. J. & Msomi, N. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. <i>medRxiv</i> (2021). Riddell, A. C., Kele, B., Harris, K., Bible, J., Murphy, M., Dakshina, S., Storey, N., Owoyemi, D., Pade, C., Gibbons, J. M., Harrington, D., Alexander, E., McKnight, Á. & Cutino-Moguel, T.
549 550		Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced HIV disease. <i>Clin Infect Dis</i> (2022). PMC9213850. 10.1093/cid/ciac409
551 552 553 554 555 556 557 558 559	7	<ul> <li>Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., Roberts, D. J., Chandra, A., Temperton, N.,</li> <li>Collaboration, CN. B. C, Consortium, CG. U., Sharrocks, K., Blane, E., Modis, Y., Leigh, K.</li> <li>E., Briggs, J. A. G., van Gils, M. J., Smith, K. G. C., Bradley, J. R., Smith, C., Doffinger, R., Ceron-Gutierrez, L., Barcenas-Morales, G., Pollock, D. D., Goldstein, R. A., Smielewska, A., Skittrall, J. P., Gouliouris, T., Goodfellow, I. G., Gkrania-Klotsas, E., Illingworth, C. J. R., McCoy, L. E. &amp; Gupta, R. K. SARS-CoV-2 evolution during treatment of chronic infection. <i>Nature</i> 592, 277-282 (2021). PMC7610568. 10.1038/s41586-021-03291-y</li> </ul>
560 561 562 563 564 565 566 566 567 568	8 9 10	<ul> <li>Peacock, T. P., Penrice-Randal, R., Hiscox, J. A. &amp; Barclay, W. S. SARS-CoV-2 one year on: evidence for ongoing viral adaptation. <i>The Journal of General Virology</i> <b>102</b> (2021).</li> <li>Jensen, B., Luebke, N., Feldt, T., Keitel, V., Brandenburger, T., Kindgen-Milles, D., Lutterbeck, M., Freise, N., Schoeler, D. &amp; Haas, R. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health Eur. 2021; 8: 100164. <i>J. LANEPE</i> (2021).</li> <li>Baang, J. H., Smith, C., Mirabelli, C., Valesano, A. L., Manthei, D. M., Bachman, M. A., Wobus, C. E., Adams, M., Washer, L., Martin, E. T. &amp; Lauring, A. S. Prolonged Severe Acute</li> </ul>
569 570		Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. <i>J Infect Dis</i> <b>223</b> , 23-27 (2021). PMC7797758. 10.1093/infdis/jiaa666

571

11 572 Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, 573 H. H., Boucau, J., Bowman, K., Adhikari, U. D., Winkler, M. L., Mueller, A. A., Hsu, T. Y., 574 Desjardins, M., Baden, L. R., Chan, B. T., Walker, B. D., Lichterfeld, M., Brigl, M., Kwon, D. S., 575 Kanjilal, S., Richardson, E. T., Jonsson, A. H., Alter, G., Barczak, A. K., Hanage, W. P., Yu, X. G., 576 Gaiha, G. D., Seaman, M. S., Cernadas, M. & Li, J. Z. Persistence and Evolution of SARS-CoV-2 577 in an Immunocompromised Host. N Engl J Med 383, 2291-2293 (2020). PMC7673303. 578 10.1056/NEJMc2031364 579 580 12 Avanzato, V. A., Matson, M. J., Seifert, S. N., Pryce, R., Williamson, B. N., Anzick, S. L., 581 Barbian, K., Judson, S. D., Fischer, E. R., Martens, C., Bowden, T. A., de Wit, E., Riedo, F. X. & 582 Munster, V. J. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 183, 1901-1912.e1909 (2020). 583 PMC7640888. 10.1016/j.cell.2020.10.049 584 585 13 586 Wilkinson, S. A. J., Richter, A., Casey, A., Osman, H., Mirza, J. D., Stockton, J., Quick, J., Ratcliffe, L., Sparks, N., Cumley, N., Poplawski, R., Nicholls, S. N., Kele, B., Harris, K., Peacock, 587 T. P. & Loman, N. J. Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol 588 589 8, veac050 (2022). PMC9384748. 10.1093/ve/veac050 590 591 Maponga, T. G., Jeffries, M., Tegally, H., Sutherland, A., Wilkinson, E., Lessells, R. J., Msomi, 14 592 N., van Zyl, G., de Oliveira, T. & Preiser, W. Persistent SARS-CoV-2 infection with 593 accumulation of mutations in a patient with poorly controlled HIV infection. Clin Infect Dis 594 (2022). PMC9278209. 10.1093/cid/ciac548 595 596 15 Hoffman, S. A., Costales, C., Sahoo, M. K., Palanisamy, S., Yamamoto, F., Huang, C., Verghese, 597 M., Solis, D. C., Sibai, M. & Subramanian, A. SARS-CoV-2 Neutralization Resistance Mutations 598 in Patient with HIV/AIDS, California, USA. Emerging Infectious Diseases 27 (2021). 599 Corey, L., Beyrer, C., Cohen, M. S., Michael, N. L., Bedford, T. & Rolland, M. SARS-CoV-2 16 600 Variants in Patients with Immunosuppression. N Engl J Med 385, 562-566 (2021). 601 PMC8494465. 10.1056/NEJMsb2104756 602 603 17 Tanner, J. R. & Kingsley, R. A. Evolution of Salmonella within Hosts. Trends Microbiol 26, 986-604 998 (2018). PMC6249985. 10.1016/j.tim.2018.06.001 605 606 18 Xue, K. S., Moncla, L. H., Bedford, T. & Bloom, J. D. Within-Host Evolution of Human 607 Influenza Virus. Trends Microbiol 26, 781-793 (2018). PMC6097882. 608 10.1016/j.tim.2018.02.007 609 610 19 Kistler, K. E., Huddleston, J. & Bedford, T. Rapid and parallel adaptive mutations in spike S1 611 drive clade success in SARS-CoV-2. Cell Host Microbe 30, 545-555.e544 (2022). PMC8938189. 612 10.1016/j.chom.2022.03.018 613 614 20 Lustig, G., Ganga, Y., Rodel, H., Tegally, H., Jackson, L., Cele, S., Khan, K., Jule, Z., Reedoy, K., 615 Karim, F., Bernstein, M., Moosa, M.-Y. S., Archary, D., de Oliveira, T., Lessells, R., Abdool 616 Karim, S. S. & Sigal, A. SARS-CoV-2 evolves increased infection elicited cell death and fusion 617 in an immunosuppressed individual. medRxiv, 2022.2011.2023.22282673 (2022). 618 10.1101/2022.11.23.22282673

619 620 621 622 623	21	Banda, N. K., Bernier, J., Kurahara, D. K., Kurrle, R., Haigwood, N., Sekaly, R. P. & Finkel, T. H. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. <i>J Exp Med</i> <b>176</b> , 1099-1106 (1992). PMC2119378. 10.1084/jem.176.4.1099
624 625 626 627	22	Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debatin, K. M. & Krammer, P. H. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. <i>Nature</i> <b>375</b> , 497-500 (1995). 10.1038/375497a0
628 629 630 631 632	23	Westendorp, M. O., Shatrov, V. A., Schulze-Osthoff, K., Frank, R., Kraft, M., Los, M., Krammer, P. H., Dröge, W. & Lehmann, V. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. <i>Embo j</i> <b>14</b> , 546-554 (1995). PMC398112. 10.1002/j.1460-2075.1995.tb07030.x
633 634 635 636	24	Cooper, A., García, M., Petrovas, C., Yamamoto, T., Koup, R. A. & Nabel, G. J. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. <i>Nature</i> <b>498</b> , 376-379 (2013). 10.1038/nature12274
637 638 639	25	Zeng, M., Haase, A. T. & Schacker, T. W. Lymphoid tissue structure and HIV-1 infection: life or death for T cells. <i>Trends Immunol</i> <b>33</b> , 306-314 (2012). 10.1016/j.it.2012.04.002
640 641 642 643	26	Monroe, K. M., Yang, Z., Johnson, J. R., Geng, X., Doitsh, G., Krogan, N. J. & Greene, W. C. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. <i>Science</i> <b>343</b> , 428-432 (2014). PMC3976200. 10.1126/science.1243640
644 645 646 647	27	Doitsh, G., Cavrois, M., Lassen, K. G., Zepeda, O., Yang, Z., Santiago, M. L., Hebbeler, A. M. & Greene, W. C. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. <i>Cell</i> <b>143</b> , 789-801 (2010). PMC3026834. 10.1016/j.cell.2010.11.001
648 649 650 651 652	28	Doitsh, G., Galloway, N. L., Geng, X., Yang, Z., Monroe, K. M., Zepeda, O., Hunt, P. W., Hatano, H., Sowinski, S., Muñoz-Arias, I. & Greene, W. C. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. <i>Nature</i> <b>505</b> , 509-514 (2014). PMC4047036. 10.1038/nature12940
653 654 655 656 657	29	Galloway, N. L., Doitsh, G., Monroe, K. M., Yang, Z., Muñoz-Arias, I., Levy, D. N. & Greene, W. C. Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-Tissue-Derived CD4 T Cells. <i>Cell Rep</i> <b>12</b> , 1555-1563 (2015). PMC4565731. 10.1016/j.celrep.2015.08.011
658		
659 660	30	Sepkowitz, K. A., Raffalli, J., Riley, L., Kiehn, T. E. & Armstrong, D. Tuberculosis in the AIDS era. <i>Clinical Microbiology Reviews</i> <b>8</b> , 180-199 (1995).
661	31	Bell, L. C. & Noursadeghi, M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-
662 663 664	32	Chen, L., Zody, M. C., Di Germanio, C., Martinelli, R., Mediavilla, J. R., Cunningham, M. H., Composto, K., Chow, K. F., Kordalewska, M., Corvelo, A., Oschwald, D. M., Fennessey, S.,

665 666 667 668		Zetkulic, M., Dar, S., Kramer, Y., Mathema, B., Germer, S., Stone, M., Simmons, G., Busch, M. P., Maniatis, T., Perlin, D. S. & Kreiswirth, B. N. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. <i>mSphere</i> <b>6</b> , e0048021 (2021). PMC8386433. 10.1128/mSphere.00480-21
669 670 671 672 673	33	Karatas, A., Inkaya, A. C., Demiroglu, H., Aksu, S., Haziyev, T., Cinar, O. E., Alp, A., Uzun, O., Sayinalp, N. & Goker, H. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. <i>Transfus Apher Sci</i> <b>59</b> , 102871 (2020). PMC7333597. 10.1016/j.transci.2020.102871
674 675 676 677 678 679 680 681	34	Li, Y., Choudhary, M. C., Regan, J., Boucau, J., Nathan, A., Speidel, T., Liew, M. Y., Edelstein, G. E., Kawano, Y., Uddin, R., Deo, R., Marino, C., Getz, M. A., Reynold, Z., Barry, M., Gilbert, R. F., Tien, D., Sagar, S., Vyas, T. D., Flynn, J. P., Hammond, S. P., Novack, L. A., Choi, B., Cernadas, M., Wallace, Z. S., Sparks, J. A., Vyas, J. M., Seaman, M. S., Gaiha, G. D., Siedner, M. J., Barczak, A. K., Lemieux, J. E. & Li, J. Z. SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency. <i>medRxiv</i> , 2023.2007.2031.23293441 (2023). 10.1101/2023.07.31.23293441
682 683	35	UNAIDS. HIV and AIDS Estimates South Africa 2021, 2021).
684 685 686 687 688	36	Carmona, S., Bor, J., Nattey, C., Maughan-Brown, B., Maskew, M., Fox, M. P., Glencross, D. K., Ford, N. & MacLeod, W. B. Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort. <i>Clinical Infectious Diseases</i> <b>66</b> , S111-S117 (2018). 10.1093/cid/ciy045
689 690 691 692 693 694 695	37	Chihana, M. L., Huerga, H., Van Cutsem, G., Ellman, T., Goemaere, E., Wanjala, S., Masiku, C., Szumilin, E., Etard, J. F., Maman, D. & Davies, M. A. Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa (Kenya) and Chiradzulu (Malawi). <i>Glob Health Action</i> <b>12</b> , 1679472 (2019). PMC6844432. 10.1080/16549716.2019.1679472
696 697 698 699 700 701 702 703 704 705	38	Antinori, A., Cicalini, S., Meschi, S., Bordoni, V., Lorenzini, P., Vergori, A., Lanini, S., De Pascale, L., Matusali, G., Mariotti, D., Cozzi Lepri, A., Gallì, P., Pinnetti, C., Gagliardini, R., Mazzotta, V., Mastrorosa, I., Grisetti, S., Colavita, F., Cimini, E., Grilli, E., Bellagamba, R., Lapa, D., Sacchi, A., Marani, A., Cerini, C., Candela, C., Fusto, M., Puro, V., Castilletti, C., Agrati, C., Girardi, E., Vaia, F. & Group, f. t. HV. S. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. <i>Clinical Infectious Diseases</i> <b>75</b> , e552- e563 (2022). 10.1093/cid/ciac238
706 707 708 709 710	39	Spinelli, M. A., Lynch, K. L., Yun, C., Glidden, D. V., Peluso, M. J., Henrich, T. J., Gandhi, M. & Brown, L. B. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. <i>Lancet HIV</i> (2021). PMC8084354 National Institutes of Health during

conduct of the study. DVG reports personal fees from Gilead Sciences outside the submitted 711 712 work. All other authors declare no competing interests. 10.1016/S2352-3018(21)00072-2 713 714 40 Vergori, A., Cozzi Lepri, A., Cicalini, S., Matusali, G., Bordoni, V., Lanini, S., Meschi, S., 715 Iannazzo, R., Mazzotta, V., Colavita, F., Mastrorosa, I., Cimini, E., Mariotti, D., De Pascale, L., 716 Marani, A., Gallì, P., Garbuglia, A., Castilletti, C., Puro, V., Agrati, C., Girardi, E., Vaia, F., 717 Antinori, A., Amendola, A., Baldini, F., Bellagamba, R., Bettini, A., Bordi, L., Camici, M., 718 Casetti, R., Costantini, S., Cristofanelli, F., D'Alessio, C., D'Aquila, V., De Angelis, A., De Zottis, 719 F., de Pascale, L., Francalancia, M., Fusto, M., Gagliardini, R., Gramigna, G., Grassi, G., Grilli, 720 E., Grisetti, S., Iafrate, D., Lapa, D., Lorenzini, P., Marani, A., Masone, E., Marongiu, S., Mondi, 721 A., Notari, S., Ottou, S., Paulicelli, J., Pellegrino, L., Pinnetti, C., Plazzi, M. M., Possi, A., Sacchi, 722 A., Tartaglia, E. & group, H.-V. s. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nature Communications 13, 4922 (2022). 10.1038/s41467-022-723 724 32263-7 725 726 41 Vanaskova, E., Kelbich, P. & Novotny, T. Reactive synovitis of the knee joint after COVID-19 vaccination: The first ultrastructural analysis of synovial fluid. Int J Rheum Dis 25, 1324-1327 727 728 (2022). PMC9538559. 10.1111/1756-185x.14411 729 730 42 Parperis, K. & Constantinou, M. Remitting seronegative symmetrical synovitis with pitting 731 oedema following BNT162b2 mRNA COVID-19 vaccination. BMJ Case Reports 14, e244479 732 (2021). 10.1136/bcr-2021-244479 733 734 43 Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y. & Bloom, 735 J. D. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that 736 affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463-737 476.e466 (2021). PMC7869748. 10.1016/j.chom.2021.02.003 738 739 44 Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., 740 Cho, A., Agudelo, M., Finkin, S., Wang, Z., Poston, D., Muecksch, F., Hatziioannou, T., 741 Bieniasz, P. D., Robbiani, D. F., Nussenzweig, M. C., Bjorkman, P. J. & Bloom, J. D. Mapping 742 mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. 743 Nature Communications 12, 4196 (2021). 10.1038/s41467-021-24435-8 744 745 45 Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., Nussenzweig, 746 747 M. C., West, A. P., Jr. & Bjorkman, P. J. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682-687 (2020). PMC8092461. 10.1038/s41586-020-748 749 2852-1 750 751 46 Wang, M., Zhang, L., Li, Q., Wang, B., Liang, Z., Sun, Y., Nie, J., Wu, J., Su, X., Qu, X., Li, Y., 752 Wang, Y. & Huang, W. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Emerging 753 754 Microbes & Infections 11, 18-29 (2022). 10.1080/22221751.2021.2008775 755 756 47 Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Wang, Z., JC, C. 757 L., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., Schiffer, C. A., Gaebler, C., Da

758 759 760 761 762		Silva, J., Poston, D., Finkin, S., Cho, A., Cipolla, M., Oliveira, T. Y., Millard, K. G., Ramos, V., Gazumyan, A., Rutkowska, M., Caskey, M., Nussenzweig, M. C., Bjorkman, P. J., Hatziioannou, T. & Bieniasz, P. D. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> <b>54</b> , 1853-1868.e1857 (2021). PMC8323339. 10.1016/j.immuni.2021.07.008
763 764 765 766 767	48	Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A. D., Chang, J. Y., Shah, J. G., Nguyen, N., Chen, Z., Meyers, K., Yin, M. T., Sobieszczyk, M. E., Sheng, Z., Huang, Y., Liu, L. & Ho, D. D. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. <i>Nature</i> <b>608</b> , 603-608 (2022). 10.1038/s41586-022-05053-w
768 769 770 771	49	Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z. & Bloom, J. D. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. <i>Science</i> <b>371</b> , 850-854 (2021). PMC7963219. 10.1126/science.abf9302
772 773 774 775 776	50	Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J. & Landau, N. R. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. <i>EBioMedicine</i> <b>78</b> , 103944 (2022). PMC9021600. 10.1016/j.ebiom.2022.103944
777 778 779 780 781	51	Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A. J., Blumberg, L., Welch, R., Ngorima-Mabhena, N. & Mutevedzi, P. C. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa. <i>New England Journal of Medicine</i> (2022). 10.1056/NEJMoa2119658
782 783 784 785 786 787	52	Mykytyn, A. Z., Rosu, M. E., Kok, A., Rissmann, M., van Amerongen, G., Geurtsvankessel, C., de Vries, R. D., Munnink, B. B. O., Smith, D. J., Koopmans, M. P. G., Lamers, M. M., Fouchier, R. A. M. & Haagmans, B. L. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1. <i>Lancet Microbe</i> <b>4</b> , e294-e295 (2023). PMC9842387. 10.1016/s2666-5247(22)00384-6
788 789 790 791 792 793 794 795	53 54	<ul> <li>Smith, D. J., Lapedes, A. S., De Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. &amp; Fouchier, R. A. Mapping the antigenic and genetic evolution of influenza virus. <i>science</i> <b>305</b>, 371-376 (2004).</li> <li>Rössler, A., Netzl, A., Knabl, L., Schäfer, H., Wilks, S. H., Bante, D., Falkensammer, B., Borena, W., von Laer, D., Smith, D. J. &amp; Kimpel, J. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants. <i>Nat Commun</i> <b>13</b>, 7701 (2022). PMC9745279. 10.1038/s41467-022-35312-3</li> </ul>
796 797 798 799 800 801 802 803	55	Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D. G., Karim, F., Bernstein, M., Lustig, G., Archary, D., Smith, M., Ganga, Y., Jule, Z., Reedoy, K., Hwa, S. H., Giandhari, J., Blackburn, J. M., Gosnell, B. I., Abdool Karim, S. S., Hanekom, W., von Gottberg, A., Bhiman, J. N., Lessells, R. J., Moosa, M. S., Davenport, M. P., de Oliveira, T., Moore, P. L. & Sigal, A. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> (2021). 10.1038/s41586-021-04387-1

804

805 806 807 808 809 810 811	56	Khan, K., Karim, F., Cele, S., Reedoy, K., San, J. E., Lustig, G., Tegally, H., Rosenberg, Y., Bernstein, M., Jule, Z., Ganga, Y., Ngcobo, N., Mazibuko, M., Mthabela, N., Mhlane, Z., Mbatha, N., Miya, Y., Giandhari, J., Ramphal, Y., Naidoo, T., Sivro, A., Samsunder, N., Kharsany, A. B. M., Amoako, D., Bhiman, J. N., Manickchund, N., Karim, Q. A., Magula, N., Abdool Karim, S. S., Gray, G., Hanekom, W., von Gottberg, A., Milo, R., Gosnell, B. I., Lessells, R. J., Moore, P. L., de Olveira, T., Moosa, M. S. & Sigal, A. Omicron infection enhances Delta antibody immunity in vaccinated persons. <i>Nature</i> (2022). 10.1038/s41586-022-04830-x
812 813 814 815 816	57	Tepasse, P. R., Hafezi, W., Lutz, M., Kühn, J., Wilms, C., Wiewrodt, R., Sackarnd, J., Keller, M., Schmidt, H. H. & Vollenberg, R. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. <i>Br J Haematol</i> <b>190</b> , 185-188 (2020). PMC7300950. 10.1111/bjh.16896
817 818 819 820 821 822 823	58	Thornton, C. S., Huntley, K., Berenger, B. M., Bristow, M., Evans, D. H., Fonseca, K., Franko, A., Gillrie, M. R., Lin, Y. C., Povitz, M., Shafey, M., Conly, J. M. & Tremblay, A. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. <i>Antimicrob Resist Infect Control</i> <b>11</b> , 28 (2022). PMC8817557. 10.1186/s13756-022-01067-1
824 825 826 827 828	59	Spiera, R., Jinich, S. & Jannat-Khah, D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. <i>Ann Rheum Dis</i> <b>80</b> , 1357-1359 (2021). 10.1136/annrheumdis-2021-220604
829 830 831 832	60	Bonelli, M. M., Mrak, D., Perkmann, T., Haslacher, H. & Aletaha, D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. <i>Ann Rheum Dis</i> <b>80</b> , 1355-1356 (2021). 10.1136/annrheumdis-2021-220408
833 834 835	61	Crotty, S. A brief history of T cell help to B cells. <i>Nature Reviews Immunology</i> <b>15</b> , 185-189 (2015). 10.1038/nri3803
836 837 838 839 840	62	Clark, S. A., Clark, L. E., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Brusic, V., Choudhary, M. C., Regan, J., Li, J. Z., Griffiths, A. & Abraham, J. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. <i>Cell</i> <b>184</b> , 2605-2617 e2618 (2021). PMC7962548. 10.1016/j.cell.2021.03.027
841 842 843 844 845 846	63	Krause, R., Snyman, J., Shi-Hsia, H., Muema, D., Karim, F., Ganga, Y., Ngoepe, A., Zungu, Y., Gazy, I., Bernstein, M., Khan, K., Mazibuko, M., Mthabela, N., Ramjit, D., Limbo, O., Jardine, J., Sok, D., Wilson, I. A., Hanekom, W., Sigal, A., Kløverpris, H., Ndung'u, T. & Leslie, A. HIV skews the SARS-CoV-2 B cell response toward an extrafollicular maturation pathway. <i>Elife</i> <b>11</b> (2022). 10.7554/eLife.79924
847 848 849 850 851	64	Fujita, S., Uriu, K., Pan, L., Nao, N., Tabata, K., Kishimoto, M., Itakura, Y., Sawa, H., Kida, I., Tamura, T., Fukuhara, T., Ito, J., Matsuno, K. & Sato, K. Impact of imprinted immunity induced by mRNA vaccination in an experimental animal model. <i>J Infect Dis</i> (2023). 10.1093/infdis/jiad230

852 853 854 855 856	65	de Gier, B., Huiberts, A. J., Hoeve, C. E., den Hartog, G., van Werkhoven, H., van Binnendijk, R., Hahné, S. J. M., de Melker, H. E., van den Hof, S. & Knol, M. J. Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology. <i>Nature Communications</i> <b>14</b> , 4793 (2023). 10.1038/s41467-023-40195-z
857 858 859 860 861 862 863	66	Khan, K., Karim, F., Ganga, Y., Bernstein, M., Jule, Z., Reedoy, K., Cele, S., Lustig, G., Amoako, D., Wolter, N., Samsunder, N., Sivro, A., San, J. E., Giandhari, J., Tegally, H., Pillay, S., Naidoo, Y., Mazibuko, M., Miya, Y., Ngcobo, N., Manickchund, N., Magula, N., Karim, Q. A., von Gottberg, A., Abdool Karim, S. S., Hanekom, W., Gosnell, B. I., Lessells, R. J., de Oliveira, T., Moosa, M. S. & Sigal, A. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection. <i>Nat Commun</i> <b>13</b> , 4686 (2022). PMC9364294. 10.1038/s41467-022-32396-9
864 865 866 867 868 869	67	Cele, S., Gazy, I., Jackson, L., Hwa, S. H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell, B. I., Hanekom, W., Moosa, M. S., Network for Genomic Surveillance in South, A., Team, C K., Lessells, R. J., de Oliveira, T. & Sigal, A. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. <i>Nature</i> <b>593</b> , 142-146 (2021). 10.1038/s41586-021-03471-w
870 871 872		

### **Figure Legends** 873

Figure 1: Persistent SARS-CoV-2 infection and accumulation of mutations in advanced 874 **HIV disease immunosuppression.** A) SARS-CoV-2 infection through time in five participants 875 with advanced HIV disease. X-axis represents infection period and bar above each graph 876 877 represents the timing of the infection waves for each variant/strain in South Africa. Y-axis 878 represents the qPCR cycle threshold (Ct) value, inversely proportional to the SARS-CoV-2 viral titer, as detected in the combined nasopharyngeal and oropharyngeal swab. Red circles 879 represent successfully sequenced timepoints and vertical dashed lines represent Pfizer 880 BNT162b2 mRNA vaccination times. B) HIV viral loads for the participants measured in the 881 blood as RNA copies/mL. Green bars above graphs denote periods of adherence to 882 dolutegravir (DTG) based ART. C) Phylogenetic tree of the sequenced virus samples through 883 time for each participant (27: grey circles, 96: purple circles, 127: purple triangles, 127: blue 884 885 circles, 209: green circles). X-axis represents distance in mutations from ancestral clade 20A SARS-CoV-2. Tree generated using Nextclade (https://clades.nextstrain.org/). 886

Figure 2: SARS-CoV-2 clearance in advanced HIV disease immunosuppression 887 associates with emergence of a neutralizing antibody response. A) SARS-CoV-2 titers 888 889 measured as qPCR Ct through time until SARS-CoV-2 clearance for participants 27, 96, 127, 255, and 209. Clearance defined as two consecutive timepoints where SARS-CoV-2 was not 890 detected. X-axis is time in days post-SARS-CoV-2 diagnosis and is the same in all panels 891 892 which describe the same participant. Y-axis is SARS-CoV-2 titer as Ct value. B) Antibody neutralization of SARS-CoV-2 isolated from each participant. One to two autologous viruses 893 were tested per participant and are indicated on the top left of each graph by the day of 894 895 isolation (denoted by a D prefix) post-diagnosis. Numbers above bars are geometric means and error bars indicate geometric mean standard deviations of 2-4 independent experiments. 896 897 C) HIV viral load in the blood during the period of SARS-CoV-2 infection. D) CD4 T cell concentrations during the period of SARS-CoV-2 infection. Horizontal lines represent limits of 898 quantification in all panels. 899

Figure 3: Advanced HIV disease participants with unsuppressed viremia have a poor 900 vaccine response. A) Longitudinal neutralization and anti-spike antibody levels before and 901 902 after vaccination with the Pfizer BNT162b2 mRNA vaccine in the three advanced HIV disease participants who suppressed HIV at vaccination (27, 96, 127) and the two who did not (255, 903 904 209). Neutralization was tested against ancestral/D614G SARS-CoV-2 (grey), Beta variant (purple), Delta variant (blue), and Omicron BA.1 subvariant (green). Timing of vaccine doses 905 is represented by vertical dashed lines. X-axis is time in days post-first vaccine dose and 906 907 negative numbers represent pre-vaccine period. Left Y-axis is neutralization capacity per viral isolate as FRNT<sub>50</sub> and right Y-axis is anti-spike antibody level as arbitrary units (AU). B) 908 909 Longitudinal neutralization and anti-spike antibody levels before and after vaccination in five participants with no advanced HIV disease. C) Neutralization of SARS-CoV-2 D614G, Beta, 910 911 Delta and Omicron BA.1 viral isolates pre-vaccination and after last administered dose by 912 plasma from the two participants with advanced HIV disease and HIV viremia (marked with red lines), the three participants with advanced HIV disease and HIV suppression (green lines) 913 and 26 participants with no advanced HIV disease (grey lines). Y-axis is neutralization as 914 915 FRNT<sub>50</sub>. Numbers above groups are geometric means and statistical comparison is between participant FRNT<sub>50</sub> values before and after vaccination and are all \*\*\*\*p<0.0001 by the Mann-916 917 Whitney test.

918

919 Figure 4: Antigenic distances of SARS-CoV-2 evolved from ancestral and Delta infections in the hamster model. A) Substitutions and deletions in the N-terminal domain 920 (NTD) and receptor binding domain (RBD) of SARS-CoV-2 spike in 27-D190 and 255-D237. 921 Blue mutations: known antibody escape. Red mutations: mutations with global prevalence 922 923 below 0.01%. RBM: receptor binding motif. Representation and characterization based on the 924 Stanford Coronavirus Antiviral and Resistance Database (https://covdb.stanford.edu). B) Schematic of hamster infection experiment. Six animals in two independent experiments were 925 926 used per infection condition. C) Neutralization of ancestral D614G, 27-D190, 255-D237, and Omicron XBB.1.5 subvariant viruses in uninfected hamsters. D-G) Neutralization of the same 927 928 viruses at 16 days post-infection in hamsters infected with ancestral/D614G (D), 27-D190 (E), 929 255-D237 (F), and the XBB.1.5 subvariant (G). Numbers above the points and horizontal bars 930 are geometric means for the group. Significance was determined by the Mann-Whitney test 931 relative to the autologous (infecting) virus. Significant p-values from left to right were: 0.03, 932 0.002, 0.002. 0.009, 0.002. 0.009, 0.002, 0.002, 0.002, 0.002, 0.002. H) Antigenic map of 933 neutralization data presented in panels D-G. Virus strains/variants are shown as colored 934 circles and hamster plasma samples as open squares with the color corresponding to the virus 935 strain or variant used to infect the hamster. Each square on the grid correspond to a twofold 936 decrease in neutralizing capacity. Map created using Racmacs (https://acorg.github.io/Racmacs/). Parts of panel B created with BioRender.com. 937

Figure 5: Neutralization of Delta evolved virus by participants with Delta and Omicron 938 939 infection elicited immunity. A) Neutralization of the 255-D237 virus compared to the Delta 940 variant virus by plasma samples from 10 participants infected during the Delta variant infection 941 wave in South Africa. B) Neutralization of the 255-D237 virus compared to the Omicron BA.1 942 subvariant virus in plasma samples from 24 participants infected with Omicron BA.1. FRNT<sub>50</sub> 943 for one participant was out of the range of the graph but included in the calculation of the geometric mean. C) Neutralization of 255-D237 compared to Omicron BA.1 virus in plasma 944 samples from 15 vaccinated participants with Omicron BA.1 breakthrough infection. D) 945 Neutralization of the 255-D237 compared to the Omicron XBB.1.5 subvariant virus in plasma 946 samples from 8 participants infected when XBB subvariants were dominant in South Africa. 947 All samples were collected approximately 2 to 3 weeks post-diagnosis in the corresponding 948 infection period. The numbers above the points and horizontal bars are geometric means of 949 950 the group and p-values were determined by the Mann-Whitney test and were: \*\*\*\*p<0.0001, 951 \*p=0.03.

Figure S1: Antiretroviral drugs detected in plasma samples from the 5 participants with 952 advanced HIV disease. ART components assayed by LC-MS/MS were the integrase inhibitor 953 dolutegravir (DTG), the nucleotide reverse transcriptase inhibitor tenofovir (TFV), the 954 nucleoside reverse transcriptase inhibitors emtricitabine (FTC), lamivudine (3TC), abacavir 955 956 (ABC), and azidothymidine (AZT), the nonnucleoside reverse transcriptase inhibitors Efavirenz (EFV) and nevirapine (NVP), and the protease inhibitors lopinavir (LPV), ritonavir 957 (RTV), atazanavir (ATV) and darunavir (DRV). X-axis is participant study visit and y-axis is 958 HIV viral load as RNA copies/mL (above) or antiretroviral drug (below). Green or blue 959 960 rectangles indicate the corresponding drug was detected at the timepoint at a level above 3 ng/mL, the limit of detection. Green rectangles indicate the presence of components of the 961 regimen of TFV, 3TC, and DTG on which participants were initiated, and blue rectangles 962 indicate components of other regimens. 963

Figure S2: Substitutions or deletions in SARS-CoV-2 sequences of advanced HIV 964 disease participants through time. Horizontal axis indicates the SARS-CoV-2 protein where 965 substitution or deletion occurred relative to the infecting strain and vertical axis is the time 966

967 post-diagnosis the viral isolate was obtained. Analysis performed using the Stanford Coronavirus Antiviral and Resistance Database (https://covdb.stanford.edu). 968

### Figure S3: Neutralizing antibody response of participant plasma against autologous 969

970 outgrown virus at different timepoints. Representative image showing infection foci in wells

of a multi-well plate from a live virus focus forming assay of participant 209 plasma against 971

autologous virus (209-D5). Plasma samples were from timepoints pre-SARS-CoV-2 clearance 972 (D37, D110, D123) through to clearance (D187). Columns are plasma dilutions which range 973

from 1:10 to 1:1280 and rows are plasma timepoint used. Bar is 2mm. 974



Figure 1: Persistent SARS-CoV-2 infection and accumulation of mutations in advanced HIV disease immunosuppression. (A) SARS-CoV-2 infection through time in five participants with advanced HIV disease. X-axis represents infection period and bar above each graph represents the timing of the infection waves for each variant/strain in South Africa. Y-axis represents the qPCR cycle threshold (Ct) value, inversely proportional to the SARS-CoV-2 viral titer, as detected in the combined nasopharyngeal and oropharyngeal swab. Red circles represent successfully sequenced timepoints and vertical dashed lines represent Pfizer BNT162b2 mRNA vaccination times. B) HIV viral loads for the participants measured in the blood as RNA copies/mL. Green bars above graphs denote periods of adherence to dolutegravir (DTG) based ART. C) Phylogenetic tree of the sequenced virus samples through time for each participant (27: grey circles, 96: purple circles, 127: purple triangles, 127: blue circles, 209: green circles). X-axis represents distance in mutations from ancestral clade 20A SARS-CoV-2. Tree generated using Nextclade (https://clades.nextstrain.org/).



Figure 2: SARS-CoV-2 clearance in advanced HIV disease immunosuppression associates with emergence of a neutralizing antibody response. A) SARS-CoV-2 titers measured as qPCR Ct through time until SARS-CoV-2 clearance for participants 27, 96, 127, 255, and 209. Clearance defined as two consecutive timepoints where SARS-CoV-2 was not detected. X-axis is time in days post-SARS-CoV-2 diagnosis and is the same in all panels which describe the same participant. Yaxis is SARS-CoV-2 titer as Ct value. B) Antibody neutralization of SARS-CoV-2 isolated from each participant. One to two autologous viruses were tested per participant and are indicated on the top left of each graph by the day of isolation (denoted by a D prefix) post-diagnosis. Numbers above bars are geometric means and error bars indicate geometric mean standard deviations of 2-4 independent experiments. C) HIV viral load in the blood during the period of SARS-CoV-2 infection. D) CD4 T cell concentrations during the period of SARS-CoV-2 infection. Horizontal lines represent limits of quantification in all panels.



Figure 3: Advanced HIV disease participants with unsuppressed viremia have a poor vac**cine response.** A) Longitudinal neutralization and anti-spike antibody levels before and after vaccination with the Pfizer BNT162b2 mRNA vaccine in the three advanced HIV disease participants who suppressed HIV at vaccination (27, 96, 127) and the two who did not (255, 209). Neutralization was tested against ancestral/D614G SARS-CoV-2 (grey), Beta variant (purple), Delta variant (blue), and Omicron BA.1 subvariant (green). Timing of vaccine doses is represented by vertical dashed lines. Xaxis is time in days post-first vaccine dose and negative numbers represent pre-vaccine period. Left Y-axis is neutralization capacity per viral isolate as  $FRNT_{50}$  and right Y-axis is anti-spike antibody level as arbitrary units (AU). B) Longitudinal neutralization and anti-spike antibody levels before and after vaccination in five participants with no advanced HIV disease. C) Neutralization of SARS-CoV-2 D614G, Beta, Delta and Omicron BA.1 viral isolates pre-vaccination and after last administered dose by plasma from the two participants with advanced HIV disease and HIV viremia (marked with red lines). the three participants with advanced HIV disease and HIV suppression (green lines) and 26 participants with no advanced HIV disease (grey lines). Y-axis is neutralization as  $FRNT_{50}$ . Numbers above groups are geometric means and statistical comparison is between participant  $FRNT_{50}$  values before and after vaccination and are all \*\*\*\*p<0.0001 by the Mann-Whitney test.



Figure 4: Antigenic distances of SARS-CoV-2 evolved from ancestral and Delta infections in the hamster model. A) Substitutions and deletions in the N-terminal domain (NTD) and receptor binding domain (RBD) of SARS-CoV-2 spike in 27-D190 and 255-D237. Blue mutations: known antibody escape. Red mutations: mutations with global prevalence below 0.01%. RBM: receptor binding motif. Representation and characterization based on the Stanford Coronavirus Antiviral and Resistance Database (https://covdb.stanford.edu). B) Schematic of hamster infection experiment. Six animals in two independent experiments were used per infection condition. C) Neutralization of ancestral D614G, 27-D190, 255-D237, and Omicron XBB.1.5 subvariant viruses in uninfected hamsters. D-G) Neutralization of the same viruses at 16 days post-infection in hamsters infected with ancestral/D614G (D), 27-D190 (E), 255-D237 (F), and the XBB.1.5 subvariant (G). Numbers above the points and horizontal bars are geometric means for the group. Significance was determined by the Mann-Whitney test relative to the autologous (infecting) virus. Significant p-values from left to right were: 0.03, 0.002, 0.002, 0.009, 0.002. 0.009, 0.002, 0.002, 0.002, 0.002, 0.002. H) Antigenic map of neutralization data presented in panels D-G. Virus strains/variants are shown as colored circles and hamster plasma samples as open squares with the color corresponding to the virus strain or variant used to infect the hamster. Each square on the grid correspond to a twofold decrease in neutralizing capacity. Map created using Racmacs (https://acorg.github.io/Racmacs/). Parts of panel B created with BioRender.com.



Figure 5: Neutralization of Delta evolved virus by participants with Delta and Omicron infection elicited immunity. A) Neutralization of the 255-D237 virus compared to the Delta variant virus by plasma samples from 10 participants infected during the Delta variant infection wave in South Africa. B) Neutralization of the 255-D237 virus compared to the Omicron BA.1 subvariant virus in plasma samples from 24 participants infected with Omicron BA.1.  $FRNT_{50}$  for one participant was out of the range of the graph but included in the calculation of the geometric mean. C) Neutralization of 255-D237 compared to Omicron BA.1 virus in plasma samples from 15 vaccinated participants with Omicron BA.1 breakthrough infection. D) Neutralization of the 255-D237 compared to the Omicron XBB.1.5 subvariant virus in plasma samples from 8 participants infected when XBB subvariants were dominant in South Africa. All samples were collected approximately 2 to 3 weeks post-diagnosis in the corresponding infection period. The numbers above the points and horizontal bars are geometric means of the group and p-values were determined by the Mann-Whitney test and were: \*\*\*\*p<0.0001, \*p=0.03.



Figure S1: Antiretroviral drugs detected in plasma samples from the 5 participants with advanced HIV disease. ART components assayed by LC-MS/MS were the integrase inhibitor dolutegravir (DTG), the nucleotide reverse transcriptase inhibitor tenofovir (TFV), the nucleoside reverse transcriptase inhibitors emtricitabine (FTC), lamivudine (3TC), abacavir (ABC), and azidothymidine (AZT), the nonnucleoside reverse transcriptase inhibitors Efavirenz (EFV) and nevirapine (NVP), and the protease inhibitors lopinavir (LPV), ritonavir (RTV), atazanavir (ATV) and darunavir (DRV). X-axis is participant study visit and y-axis is HIV viral load as RNA copies/mL (above) or antiretroviral drug (below). Green or blue rectangles indicate the corresponding drug was detected at the timepoint at a level above 3 ng/mL, the limit of detection. Green rectangles indicate the presence of components of the regimen of TFV, 3TC, and DTG on which participants were initiated, and blue rectangles indicate components of other regimens.

Participant 27

	PLpro nsp4 nsp6						p6	RdRp nsp13				S											ORF3a ORF7b																	
	M196	S370	K415	A534	T656	H682	R 1449	S40	S106	G107	F108	F184	A185	P323	M666	D105	P238	A509	6d	Y28	T95	G142	Y144	R190	L244	T299	V367	K417	D427	A475	E484	F490	N501	R682	D796	A1078	V256	M	H42	
D6	1			۷	1		G						۷	L.				S				٧									к			W		٧				٦
D20		L		۷	1		G						۷	L.											del	1	F			۷	к						del			
D34		L		۷	1		G						۷	L.			L.				1				del		F			۷	к									184
D71			N	۷	1		G		del	del	del		۷	L.		A			L				del	к				т				S			Y					evo
D106			N	۷	1		G		del	del	del	٧	۷	L.	т	A			L				del	к				T	Y			S			Y					
D190			N	۷	1	Y	G	L	del	del	del		۷	L	т	A			L	н			del	к				т	Y			S	Y		Y			۷	Y	L

Participant 96

		nsp2		PLpro	nsp4	nsp8	ns	o13	nsp15	n <u>sp1</u> 6						S						OR	F3a	E	N	1	O <u>RF1</u> 0	
	P106	S263	A510	T217	L264	T 89	L176	M429	S288	1169	D80	<b>S98</b>	G476	T478	P681	Q762	D796	T883	S943	D950	L1034	S40	L94	L74	L29	182	A28	
D1		F		1	V				F	V	۷		S							N							v	1
D15		F		1	۷	1			F					к					Р						F			
D32		F	V	1	۷		F	1	F			F	1	к			Y						F	м		т		109 day
D68		F	V	1	V		F	1	F			F	1	к	н						1		F	м		т		evolution
D77		F		1	۷		F	1	F					к	н								F	м		Т		
D110	L.	F	V	1	v			1	F	V		F	1	к	н	н		1			1	L	F	м		Т	-	1

Participant 127





Figure S2: Substitutions or deletions in SARS-CoV-2 sequences of advanced HIV disease participants through time. Horizontal axis indicates the SARS-CoV-2 protein where substitution or deletion occurred relative to the infecting strain and vertical axis is the time post-diagnosis the viral isolate was obtained. Analysis performed using the Stanford Coronavirus Antiviral and Resistance Database (https://covdb.stanford.edu).



Figure S3: Neutralizing antibody response of participant plasma against autologous outgrown virus at different timepoints. Representative image showing infection foci in wells of a multi-well plate from a live virus focus forming assay of participant 209 plasma against autologous virus (209-D5). Plasma samples were from timepoints pre-SARS-CoV-2 clearance (D37, D110, D123) through to clearance (D187). Columns are plasma dilutions which range from 1:10 to 1:1280 and rows are plasma timepoint used. Bar is 2mm.

## Table S1: Participants enrolled in the study

994         n=587 (59%)         Suppressed* CD4** >200 n=259 (26%)         CD4** >200 n=35 (4%)         viremic/suppressed CD4** <200 n=113 (11%)           Age (median, IQR)         41 (32-52)         42 (31-55)         42 (35-50)         34.5 (27-38)         41 (32-47)           Female         621 (62%)         347 (59%)         193 (75%)         22 (63%)         59 (52%)           SuppO2         143 (14%)         62 (11%)         36 (14%)         8 (23%)         37 (33%)           CD4 count (median, IQR)         774.5 (467- 1035)         907.5 (676- 199.5 (676- 199.5 (1149)         901.5)         433 (283-540)         65 (23-134)           Vaccination: Current Status of Study         774.5 (467- 1035)         1149         901.5)         59 (52%)           Not vaccinated         493 (50%)         253 (43%)         127 (49%)         24 (69%)         89 (79%)           1 dose BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant*:		All	HIV-	HIV	HIV viremic	HIV
Age (median, IQR)         41 (32-52)         42 (31-55)         42 (35-50)         34.5 (27-38)         41 (32-47)           Female         621 (62%)         347 (59%)         193 (75%)         22 (63%)         59 (52%)           SuppO2         143 (14%)         62 (11%)         36 (14%)         8 (23%)         37 (33%)           CD4 count (median, IQR)         774.5 (467- 1035)         907.5 (676- 1035)         695 (478- 907.5 (676- 695 (478- 1035)         433 (283-540)         65 (23-134)           Vaccination: Current Status of Study         1035)         1149)         901.5)         42 (69%)         89 (79%)           I dose BNT162b2***         32 (3%)         18 (3%)         10 (4%)         1 (3%)         3 (3%)           I dose Ad26.COV2.S         281 (28%)         210 (36%)         59 (23%)         6 (17%)         6 (5%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant*:		994	n=587 (59%)	Suppressed* CD4** >200 n=259 (26%)	<b>CD4</b> ** <b>&gt;200</b> n=35 (4%)	viremic/suppressed CD4** <200 n=113 (11%)
Female         621 (62%)         347 (59%)         193 (75%)         22 (63%)         59 (52%)           SuppO2         143 (14%)         62 (11%)         36 (14%)         8 (23%)         37 (33%)           CD4 count (median, IQR)         774.5 (467- 1035)         907.5 (676- 1035)         695 (478- 901.5)         433 (283-540)         65 (23-134)           Vaccination: Current Status of Study         1035)         1149)         901.5)         24 (69%)         89 (79%)           Not vaccinated         493 (50%)         253 (43%)         127 (49%)         24 (69%)         89 (79%)           1 dose BNT162b2***         32 (3%)         18 (3%)         10 (4%)         1 (3%)         3 (3%)           1 dose Ad26.COV2.S         281 (28%)         210 (36%)         59 (23%)         6 (17%)         6 (5%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant*:	Age (median, IQR)	41 (32-52)	42 (31-55)	42 (35-50)	34.5 (27-38)	41 (32-47)
SuppO2         143 (14%)         62 (11%)         36 (14%)         8 (23%)         37 (33%)           CD4 count (median, IQR)         774.5 (467- 1035)         907.5 (676- 1035)         695 (478- 901.5)         433 (283-540)         65 (23-134)           Vaccination: Current Status of Study	Female	621 (62%)	347 (59%)	193 (75%)	22 (63%)	59 (52%)
CD4 count (median, IQR)         774.5 (467- 1035)         907.5 (676- 1149)         695 (478- 901.5)         433 (283-540)         65 (23-134)           Vaccination: Current Status of Study           901.5)         901.5)         901.5)         901.5)           Not vaccinated         493 (50%)         253 (43%)         127 (49%)         24 (69%)         89 (79%)           1 dose BNT162b2***         32 (3%)         18 (3%)         10 (4%)         1 (3%)         3 (3%)           1 dose Ad26.COV2.S         281 (28%)         210 (36%)         59 (23%)         6 (17%)         6 (5%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant*:            747 (15%)         86 (14%)         44 (17%)         8 (23%)         9 (8%)           Beta         135 (13%)         92 (16%)         24 (9%)         4 (11%)         15 (13%)           Delta         106 (11%)         52 (9%)         32 (12%)         3 (9%)         19 (16%)           Omicron BA.1, BA.2         97 (10%)         51 (9%)         23 (9%)         3 (9%)         20 (18%)           Omicron KBB         96 (10%)         65 (11%)         21 (8%)         2 (6%) <th>SuppO2</th> <th>143 (14%)</th> <th>62 (11%)</th> <th>36 (14%)</th> <th>8 (23%)</th> <th>37 (33%)</th>	SuppO2	143 (14%)	62 (11%)	36 (14%)	8 (23%)	37 (33%)
Vaccination: Current Status of Study           Not vaccinated         493 (50%)         253 (43%)         127 (49%)         24 (69%)         89 (79%)           1 dose BNT162b2***         32 (3%)         18 (3%)         10 (4%)         1 (3%)         3 (3%)           1 dose Ad26.COV2.S         281 (28%)         210 (36%)         59 (23%)         6 (17%)         6 (5%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant <sup>#</sup> :         Ancestral         147 (15%)         86 (14%)         44 (17%)         8 (23%)         9 (8%)           Beta         135 (13%)         92 (16%)         24 (9%)         4 (11%)         15 (13%)           Delta         106 (11%)         52 (9%)         32 (12%)         3 (9%)         19 (16%)           Omicron BA.1, BA.2         97 (10%)         51 (9%)         23 (9%)         3 (9%)         20 (18%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%) </th <th>CD4 count (median, IQR)</th> <td>774.5 (467- 1035)</td> <td>907.5 (676- 1149)</td> <td>695 (478- 901.5)</td> <td>433 (283-540)</td> <td>65 (23-134)</td>	CD4 count (median, IQR)	774.5 (467- 1035)	907.5 (676- 1149)	695 (478- 901.5)	433 (283-540)	65 (23-134)
Not vaccinated         493 (50%)         253 (43%)         127 (49%)         24 (69%)         89 (79%)           1 dose BNT162b2***         32 (3%)         18 (3%)         10 (4%)         1 (3%)         3 (3%)           1 dose Ad26.COV2.S         281 (28%)         210 (36%)         59 (23%)         6 (17%)         6 (5%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant*:	Vaccination: Current Status of Study					
1 dose BNT162b2***         32 (3%)         18 (3%)         10 (4%)         1 (3%)         3 (3%)           1 dose Ad26.COV2.S         281 (28%)         210 (36%)         59 (23%)         6 (17%)         6 (5%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant*:	Not vaccinated	493 (50%)	253 (43%)	127 (49%)	24 (69%)	89 (79%)
1 dose Ad26.COV2.S         281 (28%)         210 (36%)         59 (23%)         6 (17%)         6 (5%)           2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant#:	1 dose BNT162b2***	32 (3%)	18 (3%)	10 (4%)	1 (3%)	3 (3%)
2 doses BNT162b2         188 (19%)         106 (18%)         63 (24%)         4 (11%)         15 (13%)           Variant#:         Ancestral         147 (15%)         86 (14%)         44 (17%)         8 (23%)         9 (8%)           Beta         135 (13%)         92 (16%)         24 (9%)         4 (11%)         15 (13%)           Delta         106 (11%)         52 (9%)         32 (12%)         3 (9%)         19 (16%)           Omicron BA.1, BA.2         97 (10%)         51 (9%)         23 (9%)         3 (9%)         20 (18%)           Omicron BA.5 related         53 (5%)         22 (4%)         14 (6%)         4 (11%)         13 (12%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           No infection (controls)         360 (36%)         219 (37%)         101 (39%)         11 (31%)         29 (26%)           Comorbidities:         Diabetes         108 (11%)         77 (13%)         26 (10%)         1 (3%)         4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	1 dose Ad26.COV2.S	281 (28%)	210 (36%)	59 (23%)	6 (17%)	6 (5%)
Variant#:         Ancestral       147 (15%)       86 (14%)       44 (17%)       8 (23%)       9 (8%)         Beta       135 (13%)       92 (16%)       24 (9%)       4 (11%)       15 (13%)         Delta       106 (11%)       52 (9%)       32 (12%)       3 (9%)       19 (16%)         Omicron BA.1, BA.2       97 (10%)       51 (9%)       23 (9%)       3 (9%)       20 (18%)         Omicron BA.5 related       53 (5%)       22 (4%)       14 (6%)       4 (11%)       13 (12%)         Omicron XBB       96 (10%)       65 (11%)       21 (8%)       2 (6%)       8 (7%)         No infection (controls)       360 (36%)       219 (37%)       101 (39%)       11 (31%)       29 (26%)         Diabetes       108 (11%)       77 (13%)       26 (10%)       1 (3%)       4 (4%)         Hypertension       199 (20%)       129 (22%)       57 (22%)       4 (11%)       9 (8%)         Cardiovascular Disease       30 (3%)       25 (4%)       3 (1%)       0 (0%)       2 (2%)	2 doses BNT162b2	188 (19%)	106 (18%)	63 (24%)	4 (11%)	15 (13%)
Ancestral147 (15%)86 (14%)44 (17%)8 (23%)9 (8%)Beta135 (13%)92 (16%)24 (9%)4 (11%)15 (13%)Delta106 (11%)52 (9%)32 (12%)3 (9%)19 (16%)Omicron BA.1, BA.297 (10%)51 (9%)23 (9%)3 (9%)20 (18%)Omicron BA.5 related53 (5%)22 (4%)14 (6%)4 (11%)13 (12%)Omicron XBB96 (10%)65 (11%)21 (8%)2 (6%)8 (7%)No infection (controls)360 (36%)219 (37%)101 (39%)11 (31%)29 (26%)Comorbidities:4 (4%)Hypertension199 (20%)129 (22%)57 (22%)4 (11%)9 (8%)Cardiovascular Disease30 (3%)25 (4%)3 (1%)0 (0%)2 (2%)	Variant <sup>#</sup> :					
Beta         135 (13%)         92 (16%)         24 (9%)         4 (11%)         15 (13%)           Delta         106 (11%)         52 (9%)         32 (12%)         3 (9%)         19 (16%)           Omicron BA.1, BA.2         97 (10%)         51 (9%)         23 (9%)         3 (9%)         20 (18%)           Omicron BA.5 related         53 (5%)         22 (4%)         14 (6%)         4 (11%)         13 (12%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           No infection (controls)         360 (36%)         219 (37%)         101 (39%)         11 (31%)         29 (26%)           Comorbidities:         Diabetes         108 (11%)         77 (13%)         26 (10%)         1 (3%)         4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Ancestral	147 (15%)	86 (14%)	44 (17%)	8 (23%)	9 (8%)
Delta         106 (11%)         52 (9%)         32 (12%)         3 (9%)         19 (16%)           Omicron BA.1, BA.2         97 (10%)         51 (9%)         23 (9%)         3 (9%)         20 (18%)           Omicron BA.5 related         53 (5%)         22 (4%)         14 (6%)         4 (11%)         13 (12%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           No infection (controls)         360 (36%)         219 (37%)         101 (39%)         11 (31%)         29 (26%)           Comorbidities:            108 (11%)         77 (13%)         26 (10%)         1 (3%)         4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Beta	135 (13%)	92 (16%)	24 (9%)	4 (11%)	15 (13%)
Omicron BA.1, BA.2         97 (10%)         51 (9%)         23 (9%)         3 (9%)         20 (18%)           Omicron BA.5 related         53 (5%)         22 (4%)         14 (6%)         4 (11%)         13 (12%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           No infection (controls)         360 (36%)         219 (37%)         101 (39%)         11 (31%)         29 (26%)           Comorbidities:             4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Delta	106 (11%)	52 (9%)	32 (12%)	3 (9%)	19 (16%)
Omicron BA.5 related         53 (5%)         22 (4%)         14 (6%)         4 (11%)         13 (12%)           Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           No infection (controls)         360 (36%)         219 (37%)         101 (39%)         11 (31%)         29 (26%)           Comorbidities:             4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Omicron BA.1, BA.2	97 (10%)	51 (9%)	23 (9%)	3 (9%)	20 (18%)
Omicron XBB         96 (10%)         65 (11%)         21 (8%)         2 (6%)         8 (7%)           No infection (controls)         360 (36%)         219 (37%)         101 (39%)         11 (31%)         29 (26%)           Comorbidities:             4 (4%)           Diabetes         108 (11%)         77 (13%)         26 (10%)         1 (3%)         4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Omicron BA.5 related	53 (5%)	22 (4%)	14 (6%)	4 (11%)	13 (12%)
No infection (controls)         360 (36%)         219 (37%)         101 (39%)         11 (31%)         29 (26%)           Comorbidities:	Omicron XBB	96 (10%)	65 (11%)	21 (8%)	2 (6%)	8 (7%)
Comorbidities:           Diabetes         108 (11%)         77 (13%)         26 (10%)         1 (3%)         4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	No infection (controls)	360 (36%)	219 (37%)	101 (39%)	11 (31%)	29 (26%)
Diabetes         108 (11%)         77 (13%)         26 (10%)         1 (3%)         4 (4%)           Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Comorbidities:					
Hypertension         199 (20%)         129 (22%)         57 (22%)         4 (11%)         9 (8%)           Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Diabetes	108 (11%)	77 (13%)	26 (10%)	1 (3%)	4 (4%)
Cardiovascular Disease         30 (3%)         25 (4%)         3 (1%)         0 (0%)         2 (2%)	Hypertension	199 (20%)	129 (22%)	57 (22%)	4 (11%)	9 (8%)
	Cardiovascular Disease	30 (3%)	25 (4%)	3 (1%)	0 (0%)	2 (2%)

\*Median HIV viral load < 500. \*\*Median CD4 count. \*\*\*At enrollment. #Variant determined by dominant circulating variant at enrollment.

### Table S2: Participants with advanced HIV disease in the study

Participant	Sex	Age range	Diagnosis	Infect. wave	Enrol. CD4	Enrol. HIV VL	1 <sup>st</sup> Vacc. Date	Vacc. CD4	Vacc. HIV VL	Time to last positive
27	F	30-39	Sep 2020	D614G	6	34151	Sep 2021	92	40	215
96	Μ	40-49	Apr 2021	Beta	4	111883	Nov 2021	59	40	110
127	Μ	30-39	Mar 2021	Beta	12	8581	Sep 2021	120	40	207
209	F	30-29	Dec 2021	Omicron	24	423817	Apr 2022	31	661666	165
255	Μ	20-29	Sep 2021	Delta	2	12041	Jun-2022	42	17813	289

### Table S3: Pfizer-vaccinated longitudinally tracked participant controls

Participant	Sex	Age	Diagnosis	Infect. wave	Enrol. CD4	Enrol. HIV VI	1 <sup>st</sup> Vacc. Date	Vacc. CD4	Vacc. HIV VI	Time to last positive
9	F	40-49	Jun 2020	D614G	706	<40	Sep 2021	658	<40	25
21	F	30-39	Jul 2020	D614G	663	<40	Sep 2021	815	<40	9
69	F	40-49	Aug 2020	D614G	702	<40	Sep 2021	757	<40	11
123	F	20-29	Feb 2021	Beta	1551	-	Sep 2021	686	-	5
149	F	50-59	Jul 2021	Delta	211	-	Sep 2021	935	-	2

### Table S4: Summary vaccinated participants (no advanced HIV disease)

	All (n=26)	HIV- (n=16)	PLWH (n=10)
Female	17 (65%)	11 (69%)	6 (60%)
Age (median, IQR)		42.5 (31-63)	47 (41-55)
Infecting Variant by Date			
Ancestral	16 (62%)	10 (63%)	6 (60%)
Beta	6 (23%)	4 (25%)	2 (20%)
Delta	4 (15%)	2 (13%)	2 (20%)
Vacc. CD4 (median, IQR)	830.5 (686-1003)	948 (765-1184.5)	707.5 (464-815)
Vacc. HIV VL (median, IQR)	-	-	40 (40-40)
Last dose to sample	24.5 (14-29)	27.5 (19-29.5)	15.5 (13-28)
(median, IQR days)			

### Table S5: Participants from different infection periods

.

	Delta* n=10	BA.1 unvaccinated n=24	BA.1 vaccinated n=15	XBB unvaccinated n=8
Female	2 (20%)	16 (67%)	9 (60%)	5 (63%)
Age (median, IQR)	47 (41-56)	31.5 (26-49)	37 (32-60)	53 (37.5-67.5)
CD4 (median, IQR)	938 (671-1238)	772 (611-1055.5)	679 (584-904)	925 (723-1102)
HIV Positive	4 (40%)	8 (33%)	4 (27%)	2 (25%)
Diagnosis to sample (median, IQR days)	23 (22-26)	21.5 (17-26.5)	22 (17-23)	13 (9-17)
Last dose to sample (median, IQR days)	23 (21-31)	-	168 (148-220)	-

\*Two participants vaccinated with 1 dose BNT162b2. Delta enrollments from 01 June 2021-31Oct 2021. Omicron BA.1 enrollments from 01Nov2021-28Feb2022. Omicron BA.4/5 enrollments from 01Mar2022-31Oct2022. Omicron XBB enrollments from 01Nov2022-01Jun2023.